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Chlamydia trachomatis is the most common sexually transmitted bacterial disease globally and 
the leading cause of infertility and preventable infectious blindness (trachoma) in the world. 
Unfortunately, there is no FDA-approved treatment specific for chlamydial infections. We  
recently reported two sulfonylpyridines that halt the growth of the pathogen. Herein, we present a 
SAR of the sulfonylpyridine molecule by introducing substituents on the aromatic regions. 
Biological evaluation studies showed that several analogues can impair the growth of C. 
trachomatis without affecting host cell viability. The compounds did not kill other bacteria, 
indicating selectivity for Chlamydia. The compounds presnted mild toxicity towards mammalian 
cell lines. The compounds were found to be non-mutagenic in a Drosophila melanogaster assay 
and exhibited a promising stability in both plasma and gastric fluid. The presented results indicate 
this scaffold is a promising starting point for the development of selective anti-chlamydial drugs. 
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Chlamydia trachomatis is a Gram-negative bacterium that infects 1.7 million people in the 
US with a ~8.8% increase in infection rates since 2013.1, 2 It is the most common reportable 
bacterial sexually transmitted infection (STI) worldwide according to recent surveillance by the 
Centers for Disease Control and Prevention.2, 3 Chlamydia, which primarily targets epithelial cells, 
is considered the leading cause of infertility and preventable infectious blindness (trachoma) in the 
world.4, 5 Perhaps the most serious issue with chlamydial infections, and a chief cause of its 
deleterious consequences, is the asymptomatic nature of the infection.6, 7 Untreated chlamydial 
infections can result in chronic sequelae, such as pelvic inflammatory disease, which can lead to 
ectopic pregnancy and tubal factor infertility.4  
The chlamydial developmental cycle commences by attachment of an infective, non-replicative 
elementary body (EB) to the plasma membrane of the host cell. Within the host cell, the EB 
remains within a host-derived vesicle, termed an inclusion.  Later the EB differentiates into its 
replicative form, the reticulate body (RB), which begins the replication process.8, 9 After multiple 
rounds of polarized division10 within the inclusion, RBs undergo a secondary differentiation to 
EBs, and the pathogen is released from the host cell starting another round of infection9, 11  
Currently, there is no vaccine nor a selective drug approved by the FDA to treat Chlamydia 
trachomatis.12, 13 The first-line antibiotics used for chlamydia infections (i.e. Azithromycin, and 
Doxycycline) are broad spectrum drugs that can affect regular functions of the commensal 
microbiota and encourage the development of bacterial resistance.14 In addition, C. trachomatis 
recurrence after antibiotic treatment remains a considerable issue that may eventually lead to 
treatment failure and the chronic sequelae associated with this pathogen.15-17 For example, repeated 
chlamydial infections at rates of ~25% for women and ~20% for men have been reported after 
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AZM treatment.18 Taking into consideration the steady increase in infection cases, the risk of 
contagion, and the rise of general bacterial resistance due to untargeted treatments, the 
development of a selective chlamydial drug is needed to meet the challenges posed by this STI. 
Several approaches are being pursued to develop specific treatments against chlamydial infections. 
Noteworthy is the seminal work of Almqvist et al. that sought to inhibit chlamydial growth by 
blocking the glucose-6-phosphate pathway.19, 20 This group have developed a novel class of 
thiazolino-2-pyridones that shown remarkable inhibitory activity and low toxicity towards 
mammalian cells. Elofsson and co-workers also reported another intriguing approach focused on 
blocking the type II fatty acid synthesis pathway (FAS II).21 The same group has prepared 
compounds with dual activity by combining key features from active compounds into hybrid 
systems.22 These important works highlight the importance of designing compounds that affect 
nontraditional bacterial targets to eradicate this pathogen. 
Another antimicrobial target that has gathered considerable attention recently are the cylindrical 
proteases.23, 24  It has been suggested that dysregulation of proteolytic enzymes is a novel approach 
to treat bacterial infections25-28 because the indiscriminate degradation of proteins can damage the 
physiology, pathogenicity, and cellular processes of the organism.29, 30 Previously, Brötz-
Oesterhelt et al. reported some cyclic acyldepsipeptides (ADEP) (Figure 1)  activate ClpP, leading 
to the death of Escherichia coli.25 Others expanded their findings showing that Clp activation can 
kill other bacteria, including Neisseria gonorrhoeae, Neisseria meningitidis, Haemophilus 
influenzae, Pseudomonas aeruginosa, and Staphylococcus aureus, through various in vitro and in 
vivo assays.31-35 Although promising, ADEPs possess some inherent limitations such as poor 
solubility, metabolic instability, fast clearance in animal studies, and challenging chemical 
synthesis.36-38 
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Building upon that precedent, Leung and coworkers combined computational chemistry and 
biochemical experiments to identify new scaffolds that can activate ClpP.35 Two of the synthesized 
molecules, named ACP1a and b (1 and 2, Figure 1), showed moderate antibacterial activity against 
N. meningitidis (64 g/mL and 16 g/mL, respectively) and H. influenzae (32 g/mL and 8 g/mL 
respectively).  Both molecules were 10-20-fold less potent than ADEP1. However, ACP1b was 
found to activate E. coli ClpP in an enzymatic assay, suggesting its potential as an antibiotic against 
this target.35 
The biological functions of Chlamydia are also hypothesized to be regulated by cylindrical 
proteases, which degrade proteins and peptides to maintain homeostasis and perhaps to regulate 
differentiation of the developmental forms.39-41 Recent work by us and others highlights the critical 
role of this degradation machinery in Chlamydia.41, 42  Four core Clp proteins have been identified 
in this organism: the caseinolytic proteases, ClpP1 and ClpP2, and two associated ATPase 
chaperones (AAA+) with diverse cellular activities 43, ClpC and ClpX.27, 44, 45 These chaperones 
bind to the axial faces of ClpP regulating its proteolytic activity.  Using the work of Leung as a 
starting point, we synthesized molecules 1 and 2 and studied their ability to affect C. trachomatis 
as well as their effects on chlamydial growth and viability. 41 We found both compounds cause a 
drastic decrease in the formation of infectious EBs, although we could not definitively assign this 
effect to a disruption in ClpP activity in Chlamydia. Based on our early report, we decided to 
optimize compounds 1 and 2 to establish structure-activity relationships (SAR).   
In the present work, we report the antichlamydial activity of new antichlamydial agents. One of 
the new molecules (compound 40) was found to affect both chlamydial inclusion numbers, size, 
and morphology in infected HEp-2 cells. In addition, we performed preliminary mechanism of 
action studies to understand the eradication process. We also investigated the antimicrobial activity 
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of the compounds against several Gram-positive and Gram-negative bacteria, as well as fungi, to 
establish their spectrum of activity. Finally, we assessed the toxicity of various compounds towards 
human cells, their mutagenicity in Drosophila melanogaster, and their plasma, simulated gastric, 
and metabolic stability utilizing human liver microsomes. The results indicate these new 
compounds are selective for Chlamydia and can be used as a starting point to develop new drugs 
selective towards this pathogen. 
 
Results and discussion 
Chemistry 
Our synthetic strategy was based on reacting a substituted sulfonyl aryl carboxylic acid with the 
desired amine.35, 41 The carboxylic acid derivatives (7a-f, Scheme 1) were prepared by reacting 2-
thioaryl derivatives (3) with an appropriate -halo ester derivative (4).35 The obtained thioether 
derivatives 5a-f were reacted, without further purification, with potassium peroxymonosulfate 
(OXONE®) in a dioxane-water mixture to provide the corresponding sulfone derivatives 6a-f. 
Hydrolysis of the ester group under mild basic condition provides the corresponding carboxylic 
acid derivatives 7a-f. The monomethyl acid derivative 7d was alternatively prepared, in two steps, 
by the reaction of 5-(trifluoromethyl)pyridine-2-thiol with 2-bromopropanoic acid followed by 
oxidation (Scheme S1).46 
  
Page 6 of 71
ACS Paragon Plus Environment





























































Scheme 1. Synthesis of key carboxylic acid intermediates 7 a-f 
 
The carboxylic acid derivatives 7a-f were activated using PYBOP and DIPEA in tetrahydrofuran 
(THF) and then reacted with 3-phenylpropylamine to yield six derivatives, 9-14 (Scheme 2).41, 47, 
48 All the prepared molecules satisfy the Lipinski rule of five (Table S1).49 PYBOP proved to be 
the best choice for this type of reaction while other coupling agents, such as HBTU and HATU 
(with or without Oxyma), only gave trace amounts of the product. The selection of THF  was also 
critical because using DMF resulted in a Smiles rearrangement reaction due to the presence of a 
sulfonyl moiety (Scheme S2).50 
 
Scheme 2. Synthesis of ACP1 analogues with modified the western part 
 
Then, five derivatives (16-20, Scheme 3) were synthesized to understand the importance of the 
thiol and chloro atoms on the eastern part of the molecule. Accordingly, the amine precursors 15a-
Page 7 of 71
ACS Paragon Plus Environment





























































b (a = 2-((2-chlorophenyl)thio)ethan-1-amine; b = 2-((4-chlorophenyl)thio)ethan-1-amine) were 
prepared as reported previously (Scheme S4)51, 52 and reacted with the carboxylic acids 7a-d. 
Scheme 3. Synthesis of ACP1b analogues by modification in the western fragment 
 
To investigate the importance of the thiol on the eastern part, we synthesized derivatives 23-31 
(Scheme 4). Firstly, we converted 2-bromoethylamine (21) into the functionalized 3-
phenoxyethylamines 22a-c (a = 2-phenoxyethan-1-amine; b = 2-(2-chlorophenoxy)ethan-1-
amine; c = 2-(4-chlorophenoxy)ethan-1-amine). These molecules were coupled to the carboxylic 
acid intermediates 7a,c,f using the conditions described above. 
 Scheme 4. ACP derivatives with oxygen in the western part 
 
To further develop SAR, we synthesized a set of compounds with restricted rotation by including 
piperazine linkers in the middle part (33-45). The carboxylic acid derivatives 7d,f were reacted 
with various piperazines (32a-j) to evaluate the effect of this substitution on the eastern region of 
the molecules, as shown in Scheme 5. This rigid linker restricts the flexibility of the side chain 
and reduces the entropic penalty of binding of the compounds to their target.53, 54  
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Antichlamydial activity. As mentioned, once EBs are internalized, they differentiate into RBs 
and remain within a membrane-bound vesicle called an inclusion.  This protects the pathogen 
during its developmental cycle. Because the inclusions are linked to the growth and replication of 
the pathogen,55, 56 we determined antichlamydial activity by analyzing the number and size of the 
inclusions using an Immunofluorescence assay (IFA).57, 58 Briefly,  HEp-2 cells were infected with 
C. trachomatis serovar L2, and the synthesized molecules were added at 50 µg/mL, 8 hours post 
infection (hpi). After 16 h (total incubation of the cells for 24 h), the inclusions were analyzed and 
compared with the control, untreated cells. The morphology and viability of the cells were 
examined under phase contrast microscopy to ensure the eradication of the inclusions was not the 
result of a reduction in viable cells due to compound toxicity (Figure 3b and SI). Table 1 shows 
the results of this pre-screening assay. 









ACP1 -  2859 + 
1 ++  29 - 
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2 +  30 - 
9 -  31 - 
10 -  33 - 
11 ++  34 - 
12 -  35 + 
13 +  36 ++ 
14 Toxic  37 ++ 
16 -  38 + 
17 -  39 - 
1859 ++  40 ++ 
19 ++  41 ++ 
2059 -  42 + 
23 -  43 - 
2459 ++  44 - 
25 ++  45 - 
26 -    
27 ++    
Compounds were tested at 50 μg/mL. *The compound’s effectiveness is a  measure of 
its ability to inhibit chlamydial inclusions and can be divided into three categories: [-] 
= Not effective; [+] = intermediate effect; [++] = effective. One compound 
demonstrated clear toxicity to the host cells and is noted.  
 
We found that analogues 9 and 10, molecules lacking the trifluoromethyl group, were 
inactive, which highlighted the importance of electron withdrawing groups at position 4. 
Meanwhile, the presence of the trifluoromethyl-substituent (compound 11) provided 
antichlamydial activity. Next, we replaced the trifluoromethyl group with a chlorine atom (13), 
obtaining an analogue with moderate activity. Two other derivatives containing an unsubstituted 
phenyl group (16, 17) and a chlorine atom on the eastern part of the molecule did not exhibit 
activity. However, the addition of the trifluoromethyl group, while keeping with the same 
substitution pattern on the eastern part (18, 19), yielded antichlamydial compounds.  
The importance of the trifluoromethyl substituent was further highlighted in derivatives 
23-29, which also possess an aryl ether group. Surprisingly, three molecules contained a 
trifluoromethyl group and were still inactive against Chlamydia: compounds 20, 30, and 31.  Note 
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that this inactive compounds possess a chlorine atom at the para position on the eastern portion of 
the molecules. Collectively, these data suggest a detrimental effect of substitution at the para 
position. To test the importance of the sulfonyl group, a thioether derivative 14 was synthesized 
by skipping the oxidation step in scheme 2. The obtained derivative showed prominent host cell 
toxicity. Compound 12, which has one methyl group instead of the gem-dimethyl group, was found 
to be inactive.  
Next, we decided to replace the amide bond at the middle part of the core molecule with 
rigid cyclic amine (piperazine) groups to generate a series of derivatives without hydrogen bond 
donor groups (Table 1 and Table S1). Compounds 33 and 34, possessing phenyl or pyridyl groups 
attached to the piperazine moiety, lacked antichlamydial activity. In contrast, replacement of the 
phenyl group with an o-tolyl (35), 2,5-dimethyl phenyl (36), or 3,4-dichloro phenyl (37) enhanced 
antichlamydial activity. The inclusion of a methyl spacer between the piperazine and the eastern 
part, gave molecules 38 and 42, which displayed moderate activity. The fluorinated analogue of 
38, molecule 39, did not possess activity, but the chlorinated molecule (40) was active. Thus, the 
data suggest that a larger group with electron withdrawing properties is needed.  Molecules 41 and 
42 possess substituents at the meta position, and, once again, the electron withdrawing group 
enhanced activity. Finally, three derivatives (43-45) with a monomethyl group in the middle part 
exhibited no antichlamydial activity.  
After the initial assessment of antichlamydial activity, we determined the impact of the 
most active compounds in vitro by determining the number and morphology of infectious units 
(the EB), and compared their activity against two antibiotics: spectinomycin and penicillin, which 
are among the FDA approved antibiotics used to treat STDs.60, 61 We understand penicillin is not 
commonly used to treat Chlamydia since it blocks cell division and growth without eradicating the 
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bacteria but we were looking for a comparison against a common drug.62  HEp-2 cells were 
infected with C. trachomatis serovar L2, and then the selected molecules were added; 50 μg/mL 
of our compounds, 128 μg/mL of spectinomycin (2x MIC),63 and 5 units/mL of penicillin (3x 
MIC)63 8 h after infection. To accurately determine the “infectious progeny” by quantifying the 
number of chlamydiae from treated cultures as well as controls we used an inclusion forming units 
(IFU) assay as described elsewhere.62 Briefly, after 24 h, the infected cells were scraped, collected 
in chlamydia transport medium, and used to re-infect a fresh HEp-2 cell monolayer. The 
chlamydial infectivity, reported as IFUs, was determined by counting the number of fluorescent 
inclusions after immunofluorescent staining, 24 h post-secondary infection (Figures 2 and 3a) 
from a minimum of 15 fields of view using an epifluorescence microscope. We also assessed the 
morphology, size, and appearance of the chlamydial inclusions after exposure to the tested 
compounds. Among the designated compounds, derivatives 11, 24, 25, 35, 37, 40, and 41 showed 
a remarkable impact on chlamydiae. Compound 40 showed superior activity than spectinomycin, 
which was used at a concentration roughly 2.5 fold higher (128 μg/mL) and on par with penicillin 
(5 U/mL ~ 3 μg/mL).64 The immunofluorescent staining (Figure 3a) revealed the inclusions were 
relatively small and irregular in cells treated with our compounds when compared with the 
untreated sample and the reference molecules. The cell morphology investigation (Figure 3b) 
supported that the tested compounds did not show any toxicity during the assay. We reasoned the 
high activity of this derivative is due to the combination of amide bond restriction in the middle 
part, the electron withdrawing group in the eastern part, and the acceptable LogP and HBD/HBA 
values (Table S1). 
Dose-response curve.  The dose-response effect was investigated for compound 40 on Chlamydia 
at six concentrations using the IFU assay described previously. As expected, compound 40 was 
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found to exhibit inhibition activity in a dose-dependent manner with an IC50 (the concentration, 
which shows 50% inclusion inhibition) of 5.2 μg/mL (Figure 4a). The dose-response curve 
revealed a high reduction of chlamydial progeny in a consistent way (Figure 4a). Besides affecting 
progeny yields, the immunofluorescence images showed an increase in the number and size of 
chlamydial inclusions as the concentration of the compound decreased (Figure 4).  Compound 40 
reduced the chlamydial infection at both 100 and 50 μg/mL and still maintained good activity up 
to a concentration of 12.5 μg/mL, with inclusion yields around 60% lower than the untreated cells. 
We did not observe cell toxicity at 100 μg/mL, which supports the tolerability of 40. 
Antichlamydial effect of ACP derivatives in comparison with two marketed drugs. We further 
tested the activity of compound 40 at 50 µg/mL and 5.20 µg/mL (IC50 value) against our lead 
compound (ACP1b) at 50 µg/mL, and two frontline antibiotics, Azithromycin and Doxycycline,  
at their reported minimal chlamydicidal concentrations (MCCs), (4 µg/mL and at 1 µg/mL, 
respectively).65-68 We confirmed our lead compound (ACP1b) and compound 40 showed good 
inhibitory activity against chlamydiae (Figure 5a).  The four testedcompounds elicited a notable 
impact on the size as well as the number of the inclusions (Figure 5b). Despite the reported 
treatment efficacy of both drugs,69 these antibiotics are associated with two major concerns. The 
first is treatment failure rate, which can reach 22% and lead to repeat infections, and existing 
complications associated with chlamydial infections.70 The second concern involves bacterial 
resistance that can be triggered by these broad spectrum therapies (in both Chlamydia and other 
normal flora bacteria)71-74 and can lead to chlamydial persistence.75-77 Given these concerns and 
the promising activity of our compounds, we consider ACP a new scaffold with a unique 
mechanism of action that can serve as a starting point to generate new antichlamydial agents. 
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Mechanism of action. Antibiotics can be bacteriostatic, stop growth or reproduction by targeting 
essential functions such as cell wall growth, or bactericidal, which kills the bacteria.78 To classify 
compound 40, we treated human cells 8 hpi with 50 μg/mL of the molecule, followed by incubation 
for an additional 16 h. Subsequently, the drug was washed out before the infected cells were further 
incubated for another 24 h. As seen in Figure 6a, compound 40 reduced the inclusion yield as 
expected but, 24h after drug washout, the number of inclusions increased by ~1 log in comparison 
with untreated cells, suggesting a bacteriostatic mechanism of action. Further, incubation of the 
infected cells with 40 for 48 h led to higher inclusion output suggesting a loss of the drug activity 
via metabolic degradation, development of resistance (unlikely on the time frame of the 
experiment) or an increase on the total number of inclusions at the end of the cycle, which cannot 
be eradicated by the drug, or a combination of the three. Additional studies are needed to 
understand this result. 
Although the EB numbers increased after drug removal or incubation for additional 24 h, we 
noticed a reduction in the inclusion size and loss in inclusion morphology reflecting a lack of  
development of the pathogen, which suggests the impact of our compounds on chlamydial growth 
(Figure 6b). Generally, the static effect of these compounds was consistent with a general 
mechanism depending on inhibition of protein turnover inside the chlamydial organisms. 
Bacteriostatic drugs can help in treatment of chlamydia infections since the progression of 
Chlamydia into a latent form and the clearance of bacteria are not only dependent on the antibiotic 
category but also on the capability of the host cells to eliminate the bacteria.79  
In vitro protease activity. The presented compounds are analogues to known ClpP activators.41, 
59   Therefore, we tested the ability of selected compounds to stimulate ClpP-dependent protein 
degradation in vitro in the absence of a AAA+ chaperone. The protease activities of recombinant 
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ClpP1 and ClpP2 from C. trachomatis L2, recombinant ClpP from E. coli, and recombinant ClpP 
from human and mouse cells (mitochondrially localized) were measured in the presence and 
absence of ACPs (Figure 7).41 Briefly, 20 µM of FITC-labeled casein was incubated with 1 or 0.1 
(40 only) µM ClpP from E. coli,  1 µM mammalian ClpP, or 6 µM of C. trachomatis ClpP1 and 
ClpP2 at 32°C for 3 h with or without compounds. Fluorescence owing to FITC-casein degradation 
was measured every 3 minutes. In parallel, degradation of unlabeled casein was also performed 
and measured by  resolved using SDS-PAGE followed by staining with Coomassie Brilliant Blue 
(Figure S4). Derivatives 11 and 40 enabled some species of ClpP to degrade casein in the absence 
of a chaperone while little or no degradation was observed for compounds 9, 16, or 17. Importantly, 
40 did not activate human or mouse ClpP, suggesting possible selectivity of the compounds for 
the bacterial ClpP at least in reference to the ClpP from E. coli. Surprinsingly, we did not observe 
activation of chlamydial ClpP1, ClpP2 or the ClpP1/2 dimer (other than some residual 
decomposition triggerer by 9 and 11). We assessed the activity of the chlamydial ClpP1/P2 
preparations using Native PAGE to confirm oligomerization (Figure S2) and digestion of the 
fluorescent peptide Suc-Luc-Tyr-AMC (Figure S3).  This prompted us to consider the killing 
effect may be the result of ClpP inhibition.  However, we did not observe inhibition of ClpP1/P2 
activity using the Suc-Luc-Tyr-AMC fluorescent peptide assay. Also, under the conditions tested, 
we did not observe alterations in ClpP1/P2 activity in the presence of the compounds and the 
chaperones (data not shown). The results suggest that while E. coli ClpP is activated chlamydial 
ClpP function is not altered, suggesting the molecules may have a mechanism of action 
independent of this target.  
Other antimicrobial activity. To evaluate the selectivity of our molecules, we tested their 
biological activity against other lab strains and ESKAPE microorganisms and selected fungal 
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pathogens: Staphylococcus aureus JE 2, S. aureus ATCC 43300 MRSA; E. coli ATCC 25922; E. 
coli K12, P. aeruginosa ATCC 27853; K. pneumoniae ATCC 700603; Acinetobacter baumannii 
ATCC 19606; Candida albicans ATCC 90028, and Cryptococcus neoformans var. grubii H99 
ATCC 20882.  Notably, none of our compounds showed inhibitory activity against these species 
in a preliminary screening at 32 µg/mL (Table S2).  To further investigate their selectivity, we 
subjected S. aureus JE2 and E. coli K12 to concentrations up to 256 μg/mL of compounds 11, 21, 
25, 28, 35, 37, 40, 42 , and once again, bacterial death was not observed. These results indicate 
that the compounds may be selective for Chlamydia.  These data also suggest the molecules may 
not affect the normal gut flora, which in turn suggests development of widespread resistance is 
unlikely. We think the lack of activity against other microorganisms is due to the unique cell wall 
structure of C. trachomatis when compared to other bacteria and the unique developmental cycle 
of Chlamydia, which may favor the selectivity of the compounds. In support of these points, 40 
was a strong activator of the E. coli ClpP in vitro (Figure 6) without showing antibacterial 
properties towards either tested E. coli strain. 
Cytotoxicity. The previous assays not only indicated antichlamydial activity, but also low toxicity 
toward the HEp-2 host cells (Figure 5b and S1). To further examine the tolerability of the 
synthesized compounds, we evaluated their in vitro toxicity against epithelial cervix 
adenocarcinoma (HeLa 229) and human keratinocyte (HaCaT) cells. Molecules were evaluated at 
a concentration of 50 µg/mL, i.e., the highest tested concentration used in antichlamydial assays, 
and results are summarized in Figure 8. The compounds were tolerated by HeLa 229 cells (only 
20 and 24 presented viabilities less than 65%) while the normal HaCaT proved to be more sensitive 
to some of the molecules. For example, compound 40 was no toxic towards HeLa 229 cells but 
affect ~50% of the HaCaT cells. Compounds 24, 37, and 42 were more tolerated by the HaCaT 
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cells. This result is not necessarily consistent with the in vitro casein degradation data. For 
example, 11 presented toxicity towards both cells and activated mammalian ClpP but 40 did not 
activate these ClpP orthologs. Future studies will be performed to assess if the observed 
degradation data is related to a limit of detection issue with the casein assay in combination with 
an increased need for ClpP/mitochondrial function in the HaCaT cells versus the HeLa cells or to 
other off-target mechanisms of action. 
Mutagenic studies. One major concern of potential antibiotics is their mutagenesis potential, 
which can damage the host cells and facilitate the adaptation of the bacteria to the antibiotic 
pressure and other types of stress.  Accordingly, we evaluated whether the ACP derivatives were 
mutagenic towards eukaryotes using the Somatic Mutation and Recombination Tests (SMART) in 
wing-somatic cells of Drosophila melanogaster.80 This in vivo assay simultaneously detects 
mutational and mitotic recombination events and quantifies the recombinogenic activity of 
chemicals and drugs. Some antimicrobial drugs have been reported to promote DNA damage 
because of oxidative stress in the mammalian genome81-83, leading to severe side effects such as 
bone marrow depression, aplastic anemia, and leukemia. We analyzed marked trans-heterozygous 
descendants (mwh/flr3) resulting from Standard (ST) and High Bioactivation (HB) crossings, 
which were chronically exposed to ACP derivatives at three different concentrations. The 
frequency of different mutant clones was scored and the total spots, which indicate the final 
genotoxicity of each compound at different concentrations, are shown in Table 3 and Table S3.  
We found that flies treated with 11, 20, 24, 26, 40 and 41 displayed frequencies of clone formation 
(per individual) for the ST and HB crosses ranging from 0.15 to 0.45 (P <0.05) and 0.20 to 0.60 
(P <0.05), respectively, at 0.25, 0.5, and 1 mM. The flies treated with compound 26 at 1 mM 
showed a higher mutation frequency of 0.70 and 0.75 in descendants from both crossings, although 
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these were not statistically significant. Overall, the results were negative, indicating that the 
compounds are non-genotoxic in somatic cells of D. melanogaster at the concentrations tested, 
even in HB cross, which has high metabolic bioactivation. However, 26 indicated that the mutant 
spot frequencies are directly dependent on the concentration, and it is possible that concentrations 
higher than 1 mM may present mutagenic potential.  Compounds 11, 20, 24, 26, 40 and 41 did not 
show toxicity against D. melanogaster at the tested concentrations, and it was observed that the 
survival rate in the treated groups did not differ statistically from the negative control (P <0.05). 
 
Table 3 - Frequency of mutant spots in the wings of marked trans-heterozygous descendants (mwh/flr3) of D. 
melanogaster using the standard cross (ST) and marked trans-heterozygous descendants (mwh/flr3) of D. melanogaster 
using the high bioactivation (HB) after chronic treatment of larvae with 11, 40 and 41 derivatives 
 
   Spots per fly (number of spots) statistical diagnosisa  








spots (1-2 cell)b 
m = 2 
Large single 
spots (>2 cell)b 
m = 2 
Twin spots 
m = 5 
Total spots 




Control 20 0.40 (8) 0.15 (3) 0.0 (0) 0.55 (11) 10 
11 
0.25 20 0.25 (5) - 0.0 (0)- 0.0 (0) - 0.25 (5) - 5 
0.50 20 0.20 (4) - 0.0 (0) - 0.0 (0) - 0.20 (4) - 4 
1.00 20 0.35 (7) - 0.05 (1) - 0.0 (0) - 0.40 (8) - 8 
40 
0.25 20 0.20 (4) - 0.0 (0) - 0.0 (0) - 0.20 (4) - 4 
0.50 20 0.15 (3) - 0.0 (0) - 0.0 (0) - 0.15 (3) - 3 
1.00 20 0.30 (6) - 0.05 (1) - 0.0 (0) - 0.35 (7) - 7 
41 
0.25 20 0.10 (2) - 0.05 (1) - 0.0 (0) - 0.15 (3) - 3 
0.50 20 0.15 (3) - 0.15 (3) - 0.05 (1) - 0.35 (7) - 7 
1.00 20 0.20 (4) - 0.05 (1) - 0.0 (0) - 0.25 (5) - 5 
mwh/flr3 of D. melanogaster - High Bioactivation (HB) cross 
Control 20 0.25 (5) 0.10 (2) 0.05 (1) 0.40 (8) 8 
11 
0.25 20 0.15 (3) - 0.05 (1) - 0.05 (1) - 0.25 (5) - 5 
0.50 20 0.10 (2) - 0.15 (3) - 0.0 (0) - 0.25 (5) - 5 
1.00 20 0.20 (4) - 0.05 (1) - 0.05 (1) - 0.30 (6) - 6 
40 
0.25 20 0.45 (9) i 0.0 (0) - 0.0 (0) - 0.45 (9) - 9 
0.50 20 0.25 (5) - 0.0 (0) - 0.10 (2) - 0.35 (7) - 7 
1.00 20 0.50 (10) i 0.05 (1) - 0.05 (1) - 0.60 (12) - 12 
41 0.25 20 0.40 (8) - 0.05 (1)  - 0.0 (0) - 0.45 (9) - 9 
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0.50 20 0.40 (8) - 0.05 (1) - 0.05 (1) - 0.50 (10) - 10 
1.00 20 0.35 (7) - 0.10 (2) - 0.0 (0) - 0.45 (9) - 9 
aStatistical diagnoses according to Frei and Würgler [1988]. U test, two-sided; probability levels: -, negative; +, 
positive; i, inconclusive; P<0,05 vs, untreated control. bIncluding flr3 single spots.  cConsidering mwh clones from 
mwh single and twin spots. NC: Negative control. 
 
Stability studies. We investigated the in vitro metabolic stability of the compounds using liver 
microsomes and mouse plasma. The incubation with human liver microsomes (HLM) is 
considered a relevant pharmacokinetic indicator for a compound in vivo.84, 85 The metabolic half-
life (t1/2) and the intrinsic clearance (CLint) of compounds 11, 24, 25, 37, and 40 are summarized in 
Table 4. The assay revealed that all tested compounds underwent rapid modification with 
approximately 90% of the drug modified in 10 minutes as shown in Figure 9. All tested 
compounds were stable in the negative control experiment (without NADPH) up to 60 minutes. 
For compound 40 the main metabolite presented a M+16 peak (Figure S5), which may correspond 
to the N-oxidated adduct. Fragmentation spectra of both neat and 10 min incubated samples 
indicated no chemical change in the eastern part (Figure S5). This compound persisted 60 min 
post incubation with HLM. The metabolic site and the complete chemical structure of this 
metabolite is still under investigation.  
Table 4. In vitro experimental Values of T1/2, intrinsic clearance, and hepatic clearance. 
Comp. ID 
T1/2 (min) CL(int) uL/(min*mg protein) CL(int,H) mL/(min*kg bodywgt.) 
Mean SD Mean SD Mean SD 
11 6.13 0.16 113.09 3.02 890.58 23.77 
24 2.98 0.17 233.77 13.74 1840.91 108.17 
25 3.73 0.03 185.60 1.72 1461.60 13.51 
37 6.25 0.16 111.96 2.85 873.80 22.45 
40 < 2.00 NA NA  NA  
NA: Not applicable 
Then, we explored the stability of some representative compounds in mouse plasma and simulated 
gastric fluid (SGF, pH 1.2) by calculating the percentage of drug remaining after contact with both 
media. The tested compounds were incubated with diluted mouse plasma and SGF at 37 °C and 
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the samples were analyzed by HPLC-MS. As shown in Figure 10, all the tested compounds 
exhibited a high stability profile and their concentrations remained constant for up to 120 minutes. 
No modification or degradation was detected after the different incubation periods. 
 
Conclusion 
Caseinolytic protease P (ClpP) activators have been shown to eradicate bacteria and prevent 
bacterial resistance. C. trachomatis is among the few bacterial species that possess two caseinolytic 
protease paralogues, ClpP1 and ClpP2.41 The Clp protein machinery system is essential for the 
chlamydial developmental cycle, which includes differentiation between the EB and RB forms.86 
In this study, we synthesized compounds based on known ClpP activators to kill C. trachomatis.  
We found some interesting lead compounds that were able to eradicate the pathogen.  The 
biological results  allowed us to conduct initial SAR studies to identify key regions that promote 
biological action (Figure 11). Noteworthy is the fact that compounds did not present activity 
against other types of bacteria, suggesting a degree of selectivity for Chlamydia. While the the 
active compounds were able to activate the E. coli ClpP, activation of chlamydial ClpP1/2 was not 
observed as determined by diverse assays. This suggest the compounds may impact Chlamydia by 
affecting a different target. In vitro metabolic stability assays revealed these ACP derivatives were 
enzymatically transformed by liver microsomes in the first 10 minutes of incubation. Conversely, 
the compounds demonstrated good stability in mouse plasma and simulated gastric fluid. Our 
results indicate the ACP derivatives represent a promising scaffold that can be further developed 
to obtain a specific treatment for C. trachomatis infection. Studies are currently undergoing to 
understand the target of the molecules. 
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General. All reagents and solvents were used as received from commercial suppliers unless 
otherwise noted. All used solvents were dried and stored with activated molecular sieves to ensure 
dryness on the long run. All coupling reactions were carried out in dried glassware under N2 
atmosphere. Reaction progression was detected using TLC, which was performed on Merck silica 
gel IB2-F plates (0.25 mm thickness), and the spots detected using UV light source at 254 nm. 1H 
and 13CNMR spectra were run at 500 MHz in deuterated chloroform (CDCl3), or dimethyl 
sulfoxide (DMSO-d6) on a BRUKER- 500 NMR spectrometer. Chemical shifts are given in parts 
per million (ppm) on the delta (d) scale. Chemical shifts were calibrated relative to those of the 
solvents. Flash chromatography was performed on RF 200i Flash Chromatography System from 
Teledyne ISCO. Low resolution mass spectra was obtained on an Agilent 6120 or 6150 mass 
spectrometer with an electrospray ionization (ESI) source. The tested compounds possessed 
purities above 95%. The purity tests were performed on an Agilent 1200 HPLC system equipped 
with a multiple  wavelength absorbance UV detector set for 254 nM and using 5 mM C-18 
reversed-phase column with methanol and water as a mobile phase. All reported yields refer to 
isolated compounds. Marvin was used for characterizing of the physicochemical charecters of the 
synthesized compounds, Marvin 20.4, ChemAxon (https://www.chemaxon.com). 
General procedure for the synthesis of acid derivatives 7a-f: 
2-(arylthio)propanoate derivatives 5a-f. To a stirred solution of an appropriated aryl thiol 3 (3.00 
mmol) in ethanol (10 mL), were added, potassium hydroxide pellets (0.25g, 4.40 mmol) followed 
by ethyl α-bromo ester 4 (3.00 mmol) and the reaction mixture was heated at reflux for 18 h. After 
completion of the reaction, the flask content was allowed to cool down to room temperature, and 
the formed inorganic salt was removed by filtration and washed with cold ethanol. The filtrate was 
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evaporated under reduced pressure, and the oily residue was dissolved in DCM (20 mL) and 
washed with deionized water (3×10 mL) and brine solution (1×10 mL), dried over anhydrous 
Na2SO4, filtered, and concentrated under reduced pressure to afford the desired product as yellow 
oil which used in the next step without further purification. 
2-(arylsulfonyl)propanoate derivatives 6a-f. Potassium mono persulfate (OXONE®) (2.2 eq) 
was added in one portion to a solution of the 2-(arylthio)propanoate derivatives 5a-f (3.4 mmol) 
in dioxane-water 5:1 (25 mL). The formed white suspension was vigorously stirred at 23 °C for 
18 h. The white solid was filtered off, washed with dioxane, and the combined filtrate was 
concentrated under reduced pressure to remove the organic layer. The resulting aqueous solution 
was extracted with DCM (3×15 mL). The combined organic solution was dried over Na2SO4, 
filtered, and the organic solvent was removed under reduced pressure to afford the desired product 
as white solids which were used directly in the next step without further purification. 
2-(arylsulfonyl) acid derivatives 7a-f. 2-(arylsulfonyl)propanoate derivative 6a-f (3.6 mmol) was 
dissolved in a mixture of THF/Water (4:1, 20 mL), lithium hydroxide monohydrate (7.2 mmol) 
was milled and added portion wise over 30 minutes and the reaction was stirred at room 
temperature for 18 h. The organic solvent was evaporated under reduced pressure, and the aqueous 
solution was washed with DCM (1×20 mL) to remove byproducts. Then, the aqueous layer was 
cooled in an ice bath and treated with 1 N HCl to pH 2. The formed precipitate was filtered off to 
afford the desired products. The physical characters and the spectral data of separated product are 
listed below: 
2-methyl-2-(Phenylsulfonyl)propanoic acid (7a). Starting with 6a (925 mg), White solid (520 
mg, 77%).1H NMR (500 MHz, CDCl3) δ 7.89 (d, J = 7.0 Hz, 2H), 7.71-7.68 (m, 2H), 7.70 (t, J = 
7.5 Hz, 1H), 1.63 (s, 6H). 
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2-Methyl-2-(Pyridin-2-ylsulfonyl)propanoic acid (7b). Starting with 6b (925 mg), White solid 
(280 mg, 41%). 1H NMR (500 MHz, CDCl3) δ 8.77 (m, 1H), 8.14 (d, J = 8.0 Hz, 1H), 8.03 (t, J = 
8.0 Hz, 1H), 7.63–7.61 (m, 1H), 1.70 (s, 6H). 
2-Methyl-2-((4-(trifluoromethyl)phenyl)sulfonyl)propanoic acid (7c). Starting with 6c (1160 
mg), White solid (840 mg, 82%). 1H NMR (500 MHz, CDCl3) δ 8.04 (d, J = 8.5 Hz, 2H), 7.83 (d, 
J = 8.5 Hz, 2H), 1.66 (s, 6H); 19F NMR δ −63.27 (s). 
2-((5-(trifluoromethyl)pyridin-2-yl)sulfonyl)propanoic acid (7d). Starting with 6d (1120 mg), 
White solid (750 mg, 85%). 1H NMR (500 MHz, CDCl3) δ 9.01 (s, 1H), 8.253-8.250 (m, 1H), 4.75 
(q, J = 7.5 Hz, 1H), 1.74 (d, J = 7.5 Hz, 3H); 19F NMR δ −62.45 (s). 
2-Methyl-2-((5-(trifluoromethyl)pyridin-2-yl)sulfonyl)propanoic acid (7e). Starting with 6e 
(1170 mg), White fluffy solid (890 mg, 83%). 1H NMR (500 MHz, CDCl3) δ 9.02 (s, 1H), 8.27–
8.22 (m, 2H), 1.76 (s, 6H); 19F NMR δ −62.68 (s); 19F NMR δ −62.68 (s). 
2-((5-Chloropyridin-2-yl)sulfonyl)-2-methylpropanoic acid (7f). Starting with 6f (1050 mg), 
White solid (700 mg, 79%). 1H NMR (500 MHz, CDCl3) δ 8.73-8.72 (m, 1H), 8.07 (d, J = 8.5 Hz, 
1H), 7.97-7.95 (m, 1H), 1.71 (s, 6H). 
General procedures for synthesis of 2-Methyl-N-(3-Phenylpropyl)-2 (arylsulfonyl) 
propanamide (9-14): 
 A solution of 2-methyl-2-(arylsulfonyl)propanoic acid 7a-f (0.16 -0.17 mmol) in dry THF (10 
mL) was treated with a solution of  PyBOP (87 mg, 0.17 mmol) in THF (1 mL) followed by DIPEA 
(83 μL). Then, the reaction mixture was stirred at room temperature for 10 min. A solution of the 
3-phenylpropan-1-amine (0.16 mmol) in THF (1 mL) was then added dropwise. The formed 
yellow solution stirred at room temperature for 1 h. The solvent was removed under vaccum, and 
the crude product was absorbed onto silica gel and purified by flash column chromatography 
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eluting with a 0−100% gradient of EtOAc in hexanes. The physical characters and the spectral data 
of the obtained products are listed below: 
2-Methyl-N-(3-Phenylpropyl)-2-(phenylsulfonyl)propanamide (9). Starting with 7a (37 mg), 
white solid (46 mg, 84%). 1H NMR (500 MHz, CDCl3) δ 7. 81 (d, J = 7.5 Hz, 2H), 7.65 (t, J = 7.5 
Hz, 1H), 7.52 (t, J = 7.5 Hz, 2H), 7.31–7.26 (m, 2H), 7.21–7.18 (m, 3H), 7.05 (br s, 1H), 3.33 (q, 
J = 6.5 Hz, 2H), 2.70 (t, J = 6.5 Hz, 2H), 1.90 (q, J = 6.5 Hz, 2H), 1.54 (s, 6H) ; 13C NMR (125 
MHz, CDCl3) δ 167.44, 141.18, 135.10, 134.34, 130.04, 129.03, 128.54, 128.40, 126.10, 68.01, 
39.90, 33.19, 30.79, 20.93; HPLC purity, 97.1%; HRMS (m/z): [M+H]+ calcd for C19H24NO3S, 
346.1399; found, 346.1470,exact mass(monoisotopic) from  spectrum 345.1397. 
2-Methyl-N-(3-Phenylpropyl)-2-(pyridin-2-ylsulfonyl)propanamide (10). Starting with 7b (37 
mg), white solid (46 mg, 83%). 1H NMR (500 MHz, CDCl3) δ 8.66-8.65 (m, 1H), 8.03 (d, J = 7.5 
Hz, 1H), 7.92(t, J = 7.5 Hz, 1H), 7.53-7.51 (m, 1H), 7.29–7.26 (m, 1H), 7.19–7.18 (m, 4H), 3.33 
(q, J = 6.5 Hz, 2H), 2.70 (t, J = 6.5 Hz, 2H), 1.91 (q, J = 7.5 Hz, 2H), 1.60 (s, 6H) ; 13C NMR (125 
MHz, CDCl3) δ 167.76, 154.89, 150.25, 141.44, 137.94, 128.47, 128.42, 127.76, 125.99, 124.71, 
67.40, 39.94, 33.13, 30.65, 20.73; HPLC purity, 98.9%; HRMS (m/z): [M+H]+ calcd for 
C18H22N2O3S, 347.1351; found, 347.1423.exact mass(monoisotopic) from  spectrum 346.1350. 
2-Methyl-N-(3-Phenylpropyl)-2-((4-(trifluoromethyl)phenyl)sulfonyl)propanamide (11). 
Starting with 7c (48 mg), white solid (53 mg, 81%).1H NMR (500 MHz, CDCl3) δ 7.94 (d, J = 8 
Hz, 2H), 7.78 (d, J = 8.5 Hz, 2H), 7.32–7.29 (m, 2H), 7.22–7.20 (m, 3H), 6.87 (br s, 1H), 3.33 (q, 
J = 6.5 Hz, 2H ), 2.71 (t, J = 6.5 Hz, 2H ), 1.93 (q, J = 6.5 Hz, 2H), 1.55 (s, 6H) ; 13C NMR (125 
MHz, CDCl3) δ 166.94, 141.03, 138.7, 136.06, 135.80, 130.68, 128.60, 128.37, 126.11(q, J =3.75 
Hz), 126.19,121.93, 68.32, 40.02, 33.19, 30.71, 20.67; HPLC purity, 97.4%; HRMS (m/z): [M+H]+ 
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calcd for C20H22F3NO3S, 414.1272; found, 414.1345, exact mass(monoisotopic) from  spectrum 
413.1727. 
N-(3-Phenylpropyl)-2-((5-(trifluoromethyl)pyridin-2-yl)sulfonyl)propanamide (12). Starting 
with 7d (50 mg), white solid (48 mg, 68%); 1H NMR (500 MHz, CDCl3) δ: 8.97 (s, 1 H), 8.19 (s, 
2H), 7.30-7.26 (m, 2H), 7.21-7.16 (m, 3H), 6.58 (br s, 1H), 4.33 (q, J = 7.5 Hz, 1H), 3.32-3.28 (m, 
2H), 2.66 (t, J = 7.5 Hz, 2H), 1.85 (p, J = 7.5 Hz, 2H), 1.55 (d, J = 7.0 Hz, 3H); 13C NMR (125 
MHz, CDCl3) δ 163.62, 158.79, 147.39, 147.36, 141.13, 135.81, 135.78, 130.22, 128.53, 128.35, 
126.12, 123.22, 121.28, 62.55, 39.84, 33.02, 30.70, 11.47; HPLC purity, 98.3; ESIMS calcd for 
C18H19F3N2O3S  401.42 [M+H]
+. Found 401.01; HRMS (m/z): [M+H] calcd for C18H19F3N2O3S, 
401.1068; found, 401.1139, exact mass(monoisotopic) from spectrum 400.1067. 
Alternative method for the synthesis of molecule 12:  
N-(3-Phenylpropyl)-2-((5-(trifluoromethyl)pyridin-2-yl)thio)propanamide. To a solution of 
2-((5-(trifluoromethyl)pyridin-2-yl)thio)propanoic acid (0.05 g, 0.20 mmol) in dry THF (7 mL), 
PYBOP (0.08 g, 0.18 mmol) and DIPEA (70 µL, 0.5 mmol) were added and the mixture was 
stirred at room temperature for 15 min, Phenyl propylamine (28 µL, 0.20 mmol) was added. The 
reaction mixture was stirred at room temperature for 1h, thereafter, the organic solvent was 
evaporated under reduced pressure and the crude residue was purified by flash column 
chromatography to yield the desired product as yellow oil (55 mg, 75% ), 1H NMR (500 MHz, 
CDCl3)  δ: 8.69 (s, 1 H), 7.73 (d, J = 8.5 Hz, 1H), 7.29 (d, J = 8.5 Hz, 1H), 7.28-7.24 (m, 2H), 
7.19-7.16 (m, 1H), 7.08-7.06 (m, 2H), 4.47 (q, J = 7.5 Hz, 1H), 3.34-3.22 (m, 2H), 2.54 (t, J = 7.5 
Hz, 2H), 1.82-1.76 (m, 2H), 1.60 (d, J = 7.5 Hz, 3H). 
N-(3-Phenylpropyl)-2-((5-(trifluoromethyl)pyridin-2-yl)sulfonyl)propanamide (12). To a 
stirred solution of 3-phenylpropyl 2-((5-(trifluoromethyl)pyridin-2-yl) thio) propanoate (55 mg, 
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0.15 mmol)  in dioxane/water (5:1, 3 mL) in a 10 mL scintillation vial, was added in one portion, 
(160mg, 0.3 mmol) potassium mono persulfate (OXON®). The obtained white suspension was 
stirred at room temperature for 16 h. After the reaction was completed as seen by TLC, the white 
solid was filtered off, and dioxane was removed under reduced pressure. Then, the aqueous 
solution was extracted with DCM (3×5mL). The collected organic layers were dried over sodium 
sulfate, removed under reduced pressure, and purified with flash column chromatography to afford 
the desired oxidized derivative as white crystals (33 mg, 56%). 
2-((5-Chloropyridin-2-yl)sulfonyl)-2-methyl-N-(3-phenylpropyl)propanamide (13). Starting 
with 6f (42 mg), white solid (55 mg, 88%). 1H NMR (500 MHz, CDCl3) δ 8.58 (s, 1H), 7.97 (d, J 
= 8.5 Hz, 1H), 7.88–7.86 (dd, J = 8.5 Hz, J = 1.5 Hz, 1H), 7.29–7.26 (m, 2H), 7.20–7.17 (m, 3H), 
7.04 (br s, 1H), 3.30 (q, J = 6.5 Hz, 2H), 2.69 (t, J = 7.5 Hz, 2H), 1.90 (q, J = 7.5 Hz, 2H), 1.59 
(6H, s) ; 13C NMR (125 MHz, CDCl3) δ 167.46, 152.64, 149.31, 141.33, 137.51, 137.03, 128.52, 
128.40, 126.06, 125.70, 67.65, 39.98, 33.12, 30.60, 20.62; HPLC purity, 98.5%; HRMS (m/z): 
[M+H]+ calcd for C18H21ClN2O3S, 381.0961; found, 381.1033, exact mass(monoisotopic) from  
spectrum 380.0960. 
2-Methyl-N-(3-phenylpropyl)-2-((5-(trifluoromethyl)pyridin-2-yl)thio)propanamide (14). 
Starting with thioacid (50 mg), White solid (47 mg, 76%). 1H NMR (500 MHz, CDCl3) δ 8.65 (s, 
1H), 7.71 (d, J = 8.5 Hz, 1H), 7.34 (br s, 1H), 7.29 (d, J = 8.5 Hz, 1H), 7.24 (t, J = 7.5 Hz, 2H), 
7.16 (t, J = 7.5 Hz, 1H), 7.06 (d, J = 7.5 Hz, 2H), 3.26 (q, J = 7.5 Hz, 2H), 2.54 (t, J = 6.5 Hz, 2H), 
1.76 (q, J = 7.5 Hz, 2H), 1.68 (s, 6H) ; 13C NMR (125 MHz, CDCl3) δ 173.85, 162.41, 146.06, 
146.01, 141.36, 133.14, 133.11, 128.43, 128.24, 125.97, 124.59, 123.39, 123.12, 122.85, 52.77, 
39.59, 33.13, 30.91, 26.61; HPLC purity, 98.9%; HRMS (m/z): [M+H]+ calcd for C19H21F3N2OS, 
383.1327; found, 383.1397, exact mass(monoisotopic) from  spectrum 382.1324. N.B: For this 
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derivative, we hydrolyzed 100 mg of 5e using the same condition, followed by the reaction with 
phenyl propylamine. 
General procedures for synthesis of 2-((Chlorophenyl)thio]ethan-1-amine (15 a-b).51, 52 To a 
solution of sodium metal (97.0 mg, 4.22 mmol) in i-PrOH (15 mL), was added, an appropriate 
chlorothiophenol derivative (475 mg, 3.30 mmol), the reaction mixture was stirred at room 
temperature for 30 minutes. Then, 2-oxazolidinone (100 mg, 1.14 mmol) was added and the 
reaction was heated at reflux for 6 h. After reaction completion, the organic solvent was evaporated 
under vacuum, and the crude product was purified using flash column chromatography (DCM: 
Methanol 90:10) to afford the desired product as the following: 
2-((2-Chlorophenyl)thio)ethan-1-amine (15a). Colorless oil with fruity odor. (125 mg, 36%); 
1H NMR (500 MHz, CDCl3) δ: 7.38-7.31 (dd, J = 7.0 Hz, 1H 2H), 7.22-7.18 (m, 1H), 7.13-7.10 
(m, 1H), 3.03 (t, J = 6.0 Hz, 2H), 2.94 (t, J = 6.0 Hz, 2H), 1.70 (s, 2H). 
2-((4-Chlorophenyl)thio)ethan-1-amine (15b). Yellow oil with characteristic odor. (305 mg, 
88.6%); 1H NMR (500 MHz, CDCl3) δ: 7.28 (d, J = 8.5 Hz, 2H), 7.229-7.23 (m ,4H), 2.90-2.89 
(m, 2H), 1.54 (br s, 2H). 
N-(2-((chlorophenyl)thio)ethyl)-2-methyl-2-(arylsulfonyl)propanamide (16-20). To a solution 
of the appropriate carboxylic acid derivative (7a-e 0.16 – 0.22 mmol) in dry THF (5 mL), PYBOP 
(1.05 eq) and DIPEA (2.7 eq) were added followed by stirring at room temperature for 10 min 
under nitrogen atmosphere. The reaction mixture was then charged with an appropriate 
chlorophenyl thioethan-1-amine derivative (15 a-b 0.16 mmol) and stirred for 1h, after reaction 
completion, THF was evaporated under reduced pressure and the crude product was purified by 
flash column chromatography to yield the desired product: 
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N-(2-((2-chlorophenyl)thio)ethyl)-2-methyl-2-(phenylsulfonyl)propanamide (16). Starting 
with 7a (50 mg) and 15a (40 mg), white solid (70 mg, 82%);  1H NMR (500 MHz, CDCl3) δ: 7.84 
(d, J = 8.0 Hz, 2H), 7.64-7.52 (m, 1H), 7.50-7.44 (m, 2H), 7.44 - 7.37 (m, 3H include br s peak), 
7.23-7.14 (m, 1H), 7.14-7.12 (m, 1H), 3.51 (q, J = 6.5 Hz, 2H), 3.11 (t, J = 6.5 Hz, 2H), 1.55 (s, 
6H) ; 13C NMR (125 MHz, CDCl3) δ 167.91, 135.00, 134.56, 134.41, 134.12, 130.12, 129.99, 
129.85, 129.06, 127.43, 68.06, 39.19, 31.95, 20.85; HPLC purity, 95.3%; ESIMS calcd for 
C18H20ClNO3S, 397.06, Found mass [M+H]
+: 398.00; HRMS (m/z): [M+H]+ calcd for 
C18H20ClNO3S, 398.0573; found, 398.0647, exact mass(monoisotopic) from  spectrum 397.0574. 
N-(2-((4-Chlorophenyl)thio)ethyl)-2-methyl-2-(phenylsulfonyl)propanamide (17). Starting 
with 7a (50 mg) and 15b (40 mg), white solid (67 mg, 77%) ESIMS calcd for C18H20ClNO3S, 
397.06, Found mass [MH+]: 398.00; 1H NMR (500 MHz, CDCl3) δ: 7.85 (d, J = 7.5 Hz, 2H), 7.68 
(t, J = 7.5 Hz, 2H), 7.53 (t, J = 8.0 Hz, 2H), 7.40 (br s, 1H), 7.36 (d, J = 9.0 Hz, 2H), 7.29 (d, J = 
8.5 Hz, 2H), 3.49 (q, J = 6.5 Hz, 2H), 3.09 (t, J = 6.5 Hz, 2H), 1.56 (s, 6H); 13C NMR (125 MHz, 
CDCl3) δ 167.85, 134.98, 134.43, 133.30, 132.77, 131.31, 130.08, 129.33, 129.07, 68.03, 39.26, 
33.25, 20.87; HPLC purity, 98.7; ESIMS calcd for C18H20ClNO3S, 397.06, Found mass [M+H]
+: 
398.00; HRMS (m/z): [M+H]+ calcd for C18H20ClNO3S, 398.0573; found, 398.0647, exact 
mass(monoisotopic) from  spectrum 397.0575. 
N-(2-((2-Chlorophenyl)thio)ethyl)-2-methyl-2((4-(trifluoromethyl)phenyl)sulfonyl) 
propanamide (18). Starting with 7c (50 mg) and 15a (33 mg), white solid (69 mg, 87%) 1H NMR 
(500 MHz, CDCl3) δ: 7.98 (d, J = 8.0 Hz, 2H), 7.74 (d, J = 8.0 Hz, 2H), 7.43-7.38 (m, 2H), 7.30 
(br s, 1H), 7.26-7.22 (m, 1H), 7.18-7.14. (m, 1H), 3.51 (q, J = 6.5 Hz, 2H), 3.12 (t, J = 6.5 Hz, 
2H), 1.57 (s, 6H) ; 13C NMR (DMSO-d6) δ 167.46, 138.69, 134.85, 133.86, 130.78, 130.18, 
130.09, 127.47, 126.15, 126.12, 68.35, 39.13, 32.27, 20.65; HPLC purity, 97%; HRMS (m/z): 
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[M+H]+ calcd for C19H19ClF3NO3S2, 466.0447; found, 466.0522, exact mass(monoisotopic) from  
spectrum 465.0449. 
N-(2-((4-Chlorophenyl)thio)ethyl)-2-methyl-2-((4-(trifluoromethyl)phenyl)sulfonyl) 
Propanamide (19). Starting with 7c (50 mg) and 15b (33 mg), white crystals ( 65 mg, 82%); 1H 
NMR (500 MHz, CDCl3) δ: 7.96 (d, J = 8.0 Hz, 2H), 7.77 (d, J = 8.0 Hz, 2H), 7.34 (d, J = 8.5 Hz, 
2H), 7.28 (d, J = 8.5 Hz, 2H), 7.24 (br s, 1H), 3.49 (q, J = 6.0 Hz, 2H), 3.08 (t, J = 6.5 Hz, 2H), 
1.56 (s, 6H); 19F NMR δ −63.31 (s); 13C NMR (125 MHz, CDCl3) δ 167.36, 138.64, 135.98 (q, J= 
32.5 Hz), 133.14, 132.92, 131.36, 130.74, 129.38, 126.15 (q, J= 3.75 Hz), 124.08, 121.90, 68.32, 
39.26, 33.33, 20.65; 19F NMR δ −63.31 (s) ; HPLC purity, 99.2%; ESIMS calcd for 
C19H19ClF3NO3S2: 465.04, Found mass [M+H]
+: 466.0; HRMS (m/z): [M+H]+ calcd for 
C19H19ClF3NO3S2, 466.0447; found, 466.0523, exact mass(monoisotopic) from  spectrum 
465.0450. 
N-(2-((4-chlorophenyl)thio)ethyl)-2-methyl-2- )(5-(trifluoromethyl)pyridin-2-yl)sulfonyl) 
propanamide (20). Starting with 7e (50 mg) and 15b (31 mg), white solid ( 53 mg, 68%) 1H NMR 
(500 MHz, CDCl3) δ: 8.91 (s, 1H), 8.21-8.17 (m, 2H), 7.37 (br s, 1H), 7.33 (d, J = 8.5 Hz, 2H), 
7.26 (d, J = 8.5 Hz, 2H), 3.48 (q, J = 6.5 Hz, 2H), 3.09 (t, J = 6.5 Hz, 2H), 1.62 (s, 6H) ; 13C NMR 
(125 MHz, CDCl3) δ 167.09, 158.12, 147.16, 135.58, 133.44, 132.73, 131.25, 130.45, 130.18, 
129.28, 124.47, 121.27, 67.59, 39.47, 33.09, 20.71; HPLC purity, 95%; ESIMS calcd for 
C19H19ClF3NO3S2: 466.04, Found mass [M+H]
+: 467.19; HRMS (m/z): [M+H]+ calcd for 
C19H19ClF3NO3S2, 467.0447; found, 467.1023. 
Synthesis of 2-(4-Chlorophenoxy)ethan-1-amine (22c). Starting from 2-bromo ethan-1-amine 
21 (500 mg, 2.45 mmol), the synthesis of 23c was carried out over three successive steps: 
Page 29 of 71
ACS Paragon Plus Environment





























































Step 1: synthesis of tert-butyl (2-Bromoethyl)carbamate. To a stirred solution of 2-bromo 
ethan-1-amine 21 (500 mg, 2.45 mmol) in DCM (15 mL) was added triethylamine (0.45 mL). The 
solution was cooled with ice bath before a solution of di-tert-butyl dicarbonate (640 mg, 2.9 mmol) 
in DMC (5mL) was added dropwise over 15 min. The mixture was stirred at 23 °C for 12 h. After 
reaction completion (as seen by TLC) , the system was quenched with brine (15 mL), the organic 
layer washed with water (3×15mL), dried over anhydrous Na2SO4, and evaporated under reduced 
pressure to afford the N-protected molecule as a yellowish oil (480 mg, 52%) 1H NMR (500 MHz, 
CDCl3) δ: 5.01 (br s, 1H), 3.50-3.41 (m, 2H), 3.42 (t, J = 5.5 Hz, 2H), 1.41 (s, 12H). 
Step 2: synthesis of tert-butyl (2-(4-Chlorophenoxy)ethyl)carbamate. p-Chlorophenol (250 
mg, 1.95 mmol) in DMF (1mL) was added gradually to a stirred solution of tert-butyl (2-
bromoethyl) carbamate (300 mg, 1.33 mmol) followed by oven-dried potassium carbonate (280 
mg, 2.0 mmol) in DMF (3mL). The mixture was stirred at 23 °C for 24 h before the flask content 
was poured over ice-cold ether (20 mL). The ether layer was washed with 2M NaOH solution (15 
mL), Water (15 mL), and brine solution (15 mL). The ether layer was dried over Na2SO4, filtered, 
and evaporated under reduced pressure. The crude product was purified by flash column 
chromatography to afford the desired product as colorless oil (155 mg, 43%). 1H NMR (500 MHz, 
CDCl3) δ: 7.44 (d, J = 12 Hz, 2H), 6.79 (d, J = 12 Hz, 2H), 5.02 (br s, 1H), 3.96 (t, J = 5 Hz, 2H), 
3.50-3.43 (m, 2H), 1.43 (s, 12H). 
2-(4-Chlorophenoxy)ethan-1-amine (22c). To a stirred solution of the tert-butyl (2-(4-
chlorophenoxy)ethyl)carbamate (155 mg, 0.5 mmol) in DMC (3 mL) was added dropwise over 30 
min, trifluoroacetic acid (2.5 mL). The reaction mixture was stirred at 23 °C for 18 h. Then, the 
solvent was evaporated, and the crude product was dissolved in ethyl acetate (15 mL) and washed 
with 1M NaOH aqueous solution (10 mL). The organic layer was dried over anhydrous Na2SO4 
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and evaporated under reduced pressure to afford the desired product as white crystals (80 mg, 
82%).  1H NMR (500 MHz, CDCl3) δ: 7.22 (d, J = 9 Hz, 2H), 6.82 (d, J = 9 Hz, 2H),3.95 (t, J = 5 
Hz, 2H), 3.07 (t, J = 5 Hz, 2H), 1.96 (br s, 2H). 
General procedures for the synthesis of 2-methyl-N-(2-aryloxyethyl)-2-
(arylsulfonyl)propanamide (23-31). A solution of 2-methyl-2-(arylsulfonyl)propanoic acid 
7a,c,f (0.16 – 0.22 mmol) in dry THF (10 mL) in a 50 mL foil-wrapped rounded-bottom flask (to 
protect the amine derivatives from light as recommended), was treated with a solution of  PyBOP 
(87 mg, 0.17 mmol) in THF (1 mL) followed by addition of DIPEA (83 μL). The mixture was 
stirred at room temperature for 10 min. A solution of the appropriate phenoxyethan-1-amine 
derivative (0.16 mmol) in THF (1 mL) was added and the reaction mixture was allowed to stir at 
the same temperature for 1 h. The solvent was removed in vacuo, and the crude product was 
purified by flash column chromatography using ethyl acetate-hexanes (1:3) as eluent. The physical 
characters and the spectral data of the separated products are listed below: 
2-Methyl-N-(2-phenoxyethyl)-2-(phenylsulfonyl)propanamide (23). Starting with 7a (50 mg, 
0.22 mmol), white crystals (44 mg, 57%); 1H NMR (500 MHz, CDCl3) δ: 7.82 (d, J = 7.5 Hz, 2H), 
7.63 (br s, 1H), 7.55 (t, J = 7.5 Hz, 1H), 7.34-7.32 (m, 2H), 7.29-7.27 (m, 2H), 6.97 (t, J = 7.5 Hz, 
1H), 6.97 (d, J = 7.5 Hz, 1H), 4.06 (t, J = 5.0 Hz, 2H), 3.70 (q, J = 5.5 Hz, 2H), 1.60 (s, 6H); 13C 
NMR (500 MHz, CDCl3) δ 168.09, 158.39, 135.09, 134.27, 130.06, 129.69, 129.00, 121.36, 
114.56, 67.97, 65.98, 40.01, 20.71; HPLC purity, 100%; ESIMS calcd for C18H21NO4S: 347.12, 
Found mass [M+H]+: 348.08, [M+Na]+: 370.06; HRMS (m/z): [M+H]+ calcd for C18H21NO4S, 
348.1191; found, 348.1263, exact mass(monoisotopic) from  spectrum 347.1190. 
2-Methyl-N-(2-Phenoxyethyl)-2-))4-(trifluoromethyl)phenyl(sulfonyl(propenamide (24). 
Starting with 7c (50 mg, 0.16 mmol), white solid (38 mg, 54%); 1H NMR (500 MHz, CDCl3) δ: 
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7.94 (d, J = 8.0 Hz, 2H), 7.52 (br s, 1H), 7.46 (d, J = 8.0 Hz, 2H), 7.34 (t, J = 8.0 Hz, 2H), 7.03 (t, 
J = 7.5 Hz, 1H), 6.97 (d, J = 8.0 Hz, 2H), 4.06 (t, J = 5.0 Hz, 2H), 3.70 (q, J = 5.5 Hz, 2H), 1.64 
(s, 6H) ; 13C NMR (125 MHz, CDCl3) δ 167.64, 158.26, 138.69, 135.91 (q, J = 32.5 Hz), 130.68, 
129.81, 126.10 (q, J = 3.75 Hz), 124.47, 67.59, 39.47, 33.09, 20.71; HPLC purity, 100%; ESIMS 
calcd for C19H20F3NO4S: 415.11, Found mass [M+Na]
+: 438.05; HRMS (m/z): [M+H]+ calcd for 
C19H20F3NO4S, 416.1065; found, 416.1137, exact mass(monoisotopic) from  spectrum 415.1064. 
2-Methyl-N-(2-Phenoxyethyl)-2-))5-(trifluoromethyl)pyridin-2-yl(sulfonyl (propenamide 
(25). Starting with 7e (50 mg, 0.16 mmol), white solid (60 mg, 85%); 1H NMR (500 MHz, CDCl3) 
δ: 8.79 (s, 1H), 7.93 (d, J = 8.5 Hz, 1H), 7.81 (d, J = 8.5 Hz, 1H), 7.51 (br s, 1H), 7.30-7.27 (m, 
2H), 7.00-6.97 (m, 1H), 6.88 (d, J = 8.0 Hz, 2H), 4.01 (t, J = 5.0 Hz, 2H), 3.69 (q, J = 5.5 Hz, 2H), 
1.70 (s, 6H) ; 13C NMR (125 MHz, CDCl3) δ 167.84, 158.46, 158.19, 147.05, 147.02 135.47, 
147.02, 130.14 (q, J = 33.75 Hz), 124.35, 121.33, 114.51, 67.83, 66.05, 39.98, 20.55; HPLC purity, 
98.5%; ESIMS calcd for C18H19F3N2O4S: 416.10, Found mass [M+H]
+: 417.10, [M+Na]+: 439.04; 
HRMS (m/z): [M+H]+ calcd for C18H19F3N2O4S, 417.1018; found, 417.1090, exact 
mass(monoisotopic) from  spectrum 416.1018. 
N-(2-(2-Chlorophenoxy)ethyl)-2-methyl-2-(Phenylsulfonyl)propanamide (26). Starting with 
7a (50 mg, 0.22 mmol), white solid ( 40 mg, 48%); 1H NMR (500 MHz, CDCl3) δ: 7.85 (d, J = 
7.5 Hz, 2H), 7.60 (br s, 1H), 7.57 (t, J = 7.5 Hz, 2H), 7.40 (d, J = 7.5 Hz, 1H), 7.35 (m, 2H), 7.24 
(m, 1H), 6.97-6.93 (m, 2H), 4.12 (t, J = 5.0 Hz, 2H), 3.74 (q, J = 5.0 Hz, 2H), 1.60 (s, 6H); 13C 
NMR (500 MHz, CDCl3) δ 168.13, 153.95, 135.15, 134.26, 130.53, 130.14, 128.93, 127.85, 
123.26, 122.14, 113.69, 68.02, 67.34, 39.88, 20.72; HPLC purity, 100%; ESIMS calcd for 
C18H20ClNO4S: 381.08, Found mass [M+H]
+: 382.05, [M+Na]+: 404.03; HRMS (m/z): [M+H]+ 
calcd for C18H20ClNO4S, 382.0802, exact mass(monoisotopic) from  spectrum 381.0800. 
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propanamide (27). Starting with 7c (50 mg, 0.16 mmol), white solid (53 mg, 70%); 1H NMR (500 
MHz, CDCl3) δ: 7.98 (d, J = 8.5 Hz, 1H), 7.55 (d, J = 8.5 Hz, 1H), 7.52 (br s, 1H), 7.42-7.40 (m, 
1H), 7.27-7.23 (m, 1H), 6.99-6.96 (m, 1H), 6.94-6.92 (m, 1H), 4.12 (t, J = 5.0 Hz, 2H), 3.73 (q, J 
= 5.0 Hz, 2H), 1.62 (s, 6H) ; 13C NMR (500 MHz, CDCl3) δ 167.69, 153.82, 138.81, 135.90 (q, J 
= 32.5 Hz), 130.77, 130.59, 127.95, 125.97, 124.05, 123.17, 122.31, 113.66, 68.31, 67.24, 40.03, 
20.52; HPLC purity, 97.4%; ESIMS calcd for C19H19ClF3NO4S: 449.07, Found mass [M+H]
+: 
450.01, [M+Na]+: 472.00; HRMS (m/z): [M+H]+ calcd for C19H19ClF3NO4S, 450.0675; found, 
450.0751, exact mass(monoisotopic) from  spectrum 449.0678.  
N-(2-(2-Chlorophenoxy)ethyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)sulfonyl) 
propanamide (28). Starting with 7e (50 mg, 0.16 mmol), white solid (64 mg, 84%); 1H NMR 
(500 MHz, CDCl3) δ: 8.75 (s, 1H), 8.11 (d, J = 8.5 Hz, 1H), 7.81 (d, J = 8.5 Hz, 1H), 7.51 (br s, 
1H), 7.38-7.36 (m, 2H), 7.22 (t, J = 7.5 Hz, 1H), 6.96-6.92 (m, 1H), 6.81 (d, J = 8.0 Hz, 1H), 4.09 
(t, J = 5.0 Hz, 2H), 3.73 (q, J = 5.5 Hz, 2H), 1.70 (s, 6H) ; 13C NMR (DMSO-d6) δ 167.94, 158.44, 
153.93, 146.97, 146.94, 135.41, 130.49, 129.91, 127.87, 124.40, 123.16, 122.17, 113.70, 67.95, 
67.35, 39.86, 20.56; HPLC purity, 97.8%; ESIMS calcd for C18H18ClF3N2O4S: 450.06, Found 
mass [M+H]+: 451.05; HRMS (m/z): [M+H]+ calcd for C18H18ClF3N2O4S, 451.0704; found, 
450.0751, exact mass(monoisotopic) from  spectrum 450.0631. 
N-(2-(4-Chlorophenoxy)ethyl)-2-methyl-2-(phenylsulfonyl)propanamide (29). Starting with 
7a (50 mg, 0.22 mmol), white solid ( 21 mg, 25%); 1H NMR (500 MHz, CDCl3) δ: 8.12 (d, J = 
7.5 Hz, 2H), 7.58 (t, J = 7.5 Hz, 2H), 7.33 (d, J = 7.5 Hz, 2H), 7.28-7.26 (m, 2H), 6.88 (d, J = 10.5 
Hz, 2H), 4.03 (t, J = 5.0 Hz, 2H), 3.68 (q, J = 5.0 Hz, 2H), 1.58 (s, 6H); 13C NMR (125 MHz, 
CDCl3) δ 168.11, 157.01, 135.05, 134.36, 130.03, 129.57, 129.02, 126.30, 115.85, 67.97, 66.44, 
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39.87, 20.77; HPLC purity, 99.5%; ESIMS calcd for C18H20ClNO4S: 381.08, Found mass [M+H]
+: 
382.20; HRMS (m/z): [M+H]+ calcd for C18H20ClNO4S, 382.0802; found, 382.0873, exact 
mass(monoisotopic) from  spectrum 381.0800. 
N-(2-(4-Chlorophenoxy)ethyl)-2-methyl-2-((4-(trifluoromethyl)Phenyl)sulfonyl) 
propanamide (30). Starting with 7c (50 mg, 0.16 mmol), white solid ( 54 mg, 71%); 1H NMR 
(500 MHz, CDCl3) δ: 7.94 (d, J = 8.0 Hz, 2H), 7.56 (d, J = 8.5 Hz, 2H), 7.45 (br s, 1H), 7.29-7.26 
(m, 2H), 6.90-6.87 (m, 2H), 4.03 (t, J = 5.0 Hz, 2H), 3.68 (q, J = 5.5 Hz, 2H), 1.60 (s, 6H); 13C 
NMR (125 MHz, CDCl3) δ 167.60, 156.90, 138.69, 135.65 (q, J = 32.5 Hz),  , 130.67, 129.64, 
126.52, 126.11, 124.01, 115.84, 68.27, 66.37, 39.99, 20.58; 19F NMR δ −63.41 (s); HPLC purity, 
98.7%; ESIMS calcd for C19H19ClF3NO4S: 449.07, Found mass [M+H]
+: 450.03; HRMS (m/z): 
[M+H]+ calcd for C19H19ClF3NO4S, 450.0675; found, 450.0750, exact mass(monoisotopic) from  
spectrum 449.0677. 
N-(2-(4-Chlorophenoxy)ethyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)sulfonyl) 
propenamide (31). Starting with 7e (50 mg, 0.16 mmol), white solid ( 43 mg, 57%) 1H NMR (500 
MHz, CDCl3) δ: 8.76 (s, 1H), 8.13 (d, J = 8.5 Hz, 1H), 7.98 (d, J = 8.0 Hz, 1H), 7.49 (br s, 1H), 
7.22 (d, J = 8.5 Hz, 2H), 6.82 (d, J = 8.5 Hz, 2H), 4.02 (t, J = 5.0 Hz, 2H), 3.68 (q, J = 5.0 Hz, 
2H), 1.66 (s, 6H) ; 13C NMR (125 MHz, CDCl3) δ 167.90, 158.22, 157.11, 147.04, 135.47, 129.87 
(q, J = 33.75 Hz), 129.46, 126.25, 124.25, 123.38 115.85, 67.64, 66.51, 39.84, 20.54; HPLC purity, 
97.8%; ESIMS calcd for C18H18ClF3N2O4S: 450.06, Found mass [M+H]
+: 451.01, [M+Na]+: 
473.01; HRMS (m/z): [M+H]+ calcd for C18H18ClF3N2O4S, 451.0628; found, 451.0703, exact 
mass(monoisotopic) from  spectrum 450.0630. 
General procedure for synthesis of 1-(4- arylpiperazin-1-yl)-2-((5-(trifluoromethyl)pyridin-
2-yl)sulfonyl)alkyl-1-one (33-45). To a stirred solution of the appropriate carboxylic acid 
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derivative ( 7d,e 50 mg, 0.16 – 0.17 mmol) in dry THF (10 mL) were added, a solution of  PyBOP 
(87 mg, 0.17 mmol) in THF (1 mL) followed by DIPEA (83 μL). Then, the mixture was stirred at 
room temperature for 10 min under nitrogen gas before a solution of the appropriate 4-aryl 
piperazine (0.16 – 0.17 mmol) in THF (1 mL) was added. The result yellow solution was allowed 
to stir at room temperature for 1 h. The solvent was removed under reduced pressure, and the crude 
product was absorbed onto silica gel and purified by flash column chromatography using ethyl 
acetate/ hexane as eluent to afford the desired product as the following: 
2-methyl-1-(4-phenylpiperazin-1-yl)-2-((5-(trifluoromethyl)pyridin-2-yl)sulfonyl)propan-1-
one (33). Starting with 7e (50 mg, 0.16 mmol) and 1-phenylpiperazine (25 µL, 0.16 mmol), off-
white solid (42 mg, 61%); 1H NMR (500 MHz, CDCl3) δ: 8.94 (s, 1 H), 8.23 (d, J = 8.5 Hz, 1H), 
8.19 (d, J = 12.0 Hz, 1H), 7.29 (d, J = 7.5 Hz, 2H), 6.95-6.92 (m, 3H), 3.91 (s, 4H), 3.26 (s, 4H), 
1.87 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 166.62, 160.05, 146.83, 135.41, 135.40, 129.98, 
129.71, 124.57, 123.75, 121.57, 120.68, 116.61, 71.54, 49.48, 45.75, 22.90; HPLC purity, 97.49%; 
ESIMS calcd for C20H22F3N2O3S: 441.13, Found mass [M+H]
+: 442.50; HRMS (m/z): [M+H]+ 
calcd for C20H22F3N2O3S, 442.1334; found, 442.1404, exact mass(monoisotopic) from  spectrum 
441.1331. 
2-methyl-1-(4-(pyridin-2-yl)piperazin-1-yl)-2-((5-(trifluoromethyl)pyridin-2-yl)sulfonyl) 
propan-1-one (34). Starting with 7e (50 mg, 0.16 mmol) and 1-(pyridin-2-yl)piperazine (28 µL, 
0.16 mmol), off-white solid (57 mg, 81%); 1H NMR (500 MHz, CDCl3) δ: 8.94 (s, 1 H), 8.24-8.17 
(m, 3H), 7.53 (d, J = 7.0 Hz, 1H), 6.70-6.66 (m, 2H), 3.88 (s, 4H), 3.66-3.65 (m, 4H), 1.87 (s, 6H); 
13C NMR (125 MHz, CDCl3) δ 166.62, 159.93, 158.76, 147.62, 146.70, 137.98, 135.30, 129.71 
(q, J = 33.75 Hz), 124.45, 123.64, 114.00, 107.45, 71.44, 45.19, 22.73; HPLC purity, 97.69%; 
ESIMS calcd for C19H21F3N4O3S: 442.13, Found mass [M+H]
+: 443.39; HRMS (m/z): [M+H]+ 
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calcd for C19H21F3N4O3S, 443.1286; found, 443.1357, exact mass(monoisotopic) from  spectrum 
442.1284. 
2-methyl-1-(4-(o-tolyl)piperazin-1-yl)-2-((5-(trifluoromethyl)pyridin-2-yl)sulfonyl)propan-
1-one (35). Starting with 7e (50 mg, 0.16 mmol) and 1-(o-tolyl)piperazine (30 µL, 0.16 mmol), 
white solid (40 mg, 56%); 1H NMR (500 MHz, CDCl3) δ: 8.95 (s, 1 H), 8.26 (d, J = 8.0 Hz, 1H), 
8.19 (d, J = 7.5 Hz, 1H), 7.20-7.15 (m, 2H), 7.03-6.99 (m, 2H), 3.87 (s, 4H), 2.95 (s, 3H), 2.32 (s, 
3H), 1.90 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 166.75, 160.47, 150.60, 146.66, 135.26, 132.71, 
131.25, 129.75, 129.48, 126.73, 124.40, 123.88, 119.16, 71.84, 51.77, 22.76, 17.83; HPLC purity 
97.9%; ESIMS calcd for C21H24F3N2O3S: 455.16, Found mass [M+H]
+: 456.53; HRMS (m/z): 
[M+H]+ calcd for C21H24F3N2O3S, 456.1490; found, 456.1561, exact mass(monoisotopic) from  
spectrum 455.1489. 
1-(4-(2,5-dimethylphenyl)piperazin-1-yl)-2-methyl-2-((5(trifluoromethyl)pyridin-2-
yl)sulfonyl)propan-1-one (36). Starting with 7e (50 mg, 0.16 mmol) and 1-(2,5-dimethylphenyl) 
piperazine (32 µL, 0.16 mmol), white solid (65 mg, 88%); 1H NMR (500 MHz, CDCl3) δ: 8.96 (s, 
1 H), 8.26 (d, J = 8.5 Hz, 1H), 8.20 (d, J = 8.0 Hz, 1H), 7.08 (d, J = 7.5 Hz, 1H), 6.82 (m, 2H), 
3.86 (s, 4H), 2.95 (s, 4H), 2.30 (s, 3H), 2.27 (s, 3H), 1.90 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 
166.73, 160.51, 150.43, 146.64, 136.33, 135.26, 131.05, 129.39, 124.49, 124.39, 123.70, 119.92, 
71.87, 51.78, 22.76, 21.15, 17.41; HPLC purity 98.9%; ESIMS calcd for C22H26F3N3O3S: 469.16, 
Found mass [M+H]+: 470.24; HRMS (m/z): [M+H]+ calcd for C22H26F3N3O3S, 470.1647; found, 
470.1719, exact mass(monoisotopic) from  spectrum 469.1647. 
1-(4-(3,4-dichlorophenyl)piperazin-1-yl)-2-((5-(trifluoromethyl)pyridin-2-yl)sulfonyl) 
propan-1-one (37). Starting with 7e (50 mg, 0.16 mmol) and 1-(3,4-dichlorophenyl) piperazine 
(39 mg, 0.16 mmol), white crystals (53 mg, 61.5%); 1H NMR (500 MHz, CDCl3) δ: 8.91 (s, 4 H), 
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8.21-8.19 (m, 2H), 7.30-7.28 (m, J = 9.0 Hz,1H), 6.96 (s, 1H), 6.76-6.73 (m, 1H), 3.99 (m, 4H), 
3.25-3.23 (m, 4H), 1.83 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 166.38, 159.48, 150.12, 146.82, 
135.34, 133.00, 130.63, 130.03, 129.76, 124.49, 123.10, 117.64, 115.65, 71.04, 48.78, 45.50, 
22.90; HPLC purity 98.1%; ESIMS calcd for C20H20Cl2F3N3O3S: 509.06, Found mass [M+H]
+: 
510.16; HRMS (m/z): [M+H]+ calcd for C20H20Cl2F3N3O3S, 510.0555; found, 510.0636, exact 
mass(monoisotopic) from  spectrum 509.0564. 
1-(4-(3-methoxyphenyl)piperazin-1-yl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-
yl)sulfonyl)propan-1-one (38). Starting with 7e (50 mg, 0.16 mmol) and 1-(m-methoxyphenyl) 
piperazine (30 µL, 0.16 mmol), white solid (80  mg, 97.5%); 1H NMR (500 MHz, CDCl3) δ: 8.93 
(s, 1 H), 8.22 (d, J = 8.0 Hz, 1H), 8.17 (d, J = 8.5 Hz, 1H), 7.18 (t, J = 8.5 Hz, 1H), 6.54-6.52 (m, 
1H), 6.46-6.45 (m, 2H), 3.88 (s, 4H), 3.78 (s, 3H), 3.25-3.24 (s, 4H), 1.86 (s, 6H); 19F NMR δ 
−62.62 (s) ; 13C NMR (125 MHz, CDCl3) δ 166.51, 160.69, 159.94, 152.09, 146.73, 146.70 135.28, 
135.25, 129.99, 124.44, 109.06, 105.22, 102.90, 71.42, 55.24, 49.20, 22.79; HPLC purity 97.5%; 
ESIMS calcd for C21H24F3N3O4S :471.14, Found mass [M+H]
+: 472.14; HRMS (m/z): [M+H]+ 
calcd for C21H24F3N3O4S, 472.1439; found, 472.1511, exact mass(monoisotopic) from  spectrum 
471.1439. 
2-methyl-1-(4-(4-fluorobenzyl)piperazin-1-yl]2-((5-(trifluoromethyl)pyridin-2-yl)sulfonyl) 
propan-1-one (39). Starting with 7e (50 mg, 0.16 mmol) and 1-(4-fluorobenzyl)piperazine (33 
mg, 0.16 mmol), white solid (42 mg, 53%); 1H NMR (500 MHz, CDCl3) δ: 8.91 (s, 1 H), 8.22 (d, 
J = 8.5 Hz, 1H), 8.17 (d, J = 8.0 Hz, 1H), 7.28-7.25 (m, 2H), 7.27 (t, J = 8.5 Hz, 2H), 3.70 (s, 4H), 
3.48 (s, 2H), 2.47 (s, 4H), 1.87 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 166.54, 161.18, 160.49, 
146.58, 135.24, 133.12, 130.66, 130.59, 124.37, 115.29, 115.12, 71.83, 61.92, 52.74, 22.63; 19F 
NMR δ −62.61, −70.08, −71.60 ; HPLC purity, 97.9%; ESIMS calcd for C21H23F4N2O3S: 473.14, 
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Found mass [M+H]+: 474.30; HRMS (m/z): [M+H]+ calcd for C21H23F4N2O3S, 474.1396; found, 
474.1467, exact mass(monoisotopic) from  spectrum 4731394. 
2-methyl-1-(4-(4-Chlorobenzyl)piperazin-1-yl)-2-((5-(trifluoromethyl)pyridin-2-yl)sulfonyl) 
propan-1-one (40). Starting with 7e (50 mg, 0.16 mmol) and 1-(4-chlorobenzyl)piperazine (30 
µL, 0.16 mmol), white solid (69 mg, 84.1%); 1H NMR (500 MHz, CDCl3) δ: 8.91 (s, 1 H), 8.22 
(d, J = 8.0 Hz, 1H), 8.18 (d, J = 8.0 Hz, 1H), 7.31-7.28 (m, 4H), 3.73 (s, 4H), 3.52 (s, 2H), 2.51 (s, 
3H), 2.170 (s, 2H), 1.83 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 166.54, 160.51, 146.57, 136.10, 
135.26, 133.03, 130.36, 129.52 (q, J = 33.75 Hz), 128.51, 124.37, 123.69, 121.51, 71.84, 61.94, 
52.78, 45.62, 22.61; HPLC purity, 99.3%; ESIMS calcd for C21H23ClF3N3O3S: 489.11, Found 
mass [M+H]+: 490.14; HRMS (m/z): [M+H]+ calcd for C21H23ClF3N3O3S, 490.1101; found, 
490.1175, exact mass(monoisotopic) from  spectrum 489.1102. 
2-methyl-1-(4-(3-chlorobenzyl)piperazin-1-yl)-2-((5-(trifluoromethyl)pyridin-2-yl)sulfonyl) 
propan-1-one (41). Starting with 7e (50 mg, 0.16 mmol) and 1-(3-chlorobenzyl)piperazine (30 
µL, 0.16 mmol), white solid (72 mg, 88%); 1H NMR (500 MHz, CDCl3) δ: 8.91 (s, 1 H), 8.22 (d, 
J = 8.0 Hz, 1H), 8.17 (d, J = 8.0 Hz, 1H), 7.32 (s, 1H), 7.24-7.17 (m, 3H), 3.72-3.67 (m, 4H), 3.49 
(s, 2H), 2.49-2.47 (m, 4H), 1.84 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 166.56, 160.50, 146.59, 
144.60, 139.87, 135.21, 134.34, 129.63, 129.00, 127.54, 127.13, 124.36, 71.81, 62.11, 55.91, 
52.83, 22.65; HPLC purity, 98.87%; ESIMS calcd for C21H23ClF3N3O3S: 489.11, Found mass 
[M+H]+: 490.17; HRMS (m/z): [M+H]+ calcd for C21H23ClF3N3O3S, 490.1101; found, 490.1173, 
exact mass(monoisotopic) from  spectrum 489.1100. 
2-methyl-1-(4-(4-methylbenzyl)piperazin-1-yl)-2-((5-(trifluoromethyl)pyridin-2-yl)sulfonyl) 
propan-1-one (42). Starting with 7e (50 mg, 0.16 mmol) and 1-(4-methylbenzyl)piperazine (32 
mg, 0.16 mmol), white solid (40 mg, 51%); 1H NMR (500 MHz, CDCl3)  δ: 8.86 (s, 1 H), 8.22 (d, 
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J = 8.5 Hz, 1H), 8.17 (d, J = 8.0 Hz, 1H), 7.22 (d, J = 7.5 Hz, 1H), 7.14 (d, J = 7.5 Hz, 1H), 3.73 
(s, 4H), 3.55 (s, 2H), 2.53 (s, 4H), 2.34 (s, 3H), 1.84 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 
166.59, 160.64, 146.53, 137.04, 135.22, 134.17, 129.18, 129.05, 124.37, 123.70, 121.53, 71.98, 
62.47, 52.71, 45.70, 22.55, 21.11; HPLC purity, 95.9%; ESIMS calcd for C22H26F3N3O3S: 469.16, 
Found mass [M+H]+: 470.58; HRMS (m/z): [M+H]+ calcd for C22H26F3N3O3S, 470.1647; found, 
470.1722, exact mass(monoisotopic) from  spectrum 4691649. 
1-(4-(o-tolyl)piperazin-1-yl)-2-((5-(trifluoromethyl)pyridin-2-yl)sulfonyl)propan-1-one (43). 
Starting with 7d (50 mg, 0.17 mmol) and 1-(o-tolyl)piperazine (33 µL, 0.17 mmol), yellowish 
white solid (52 mg, 67%); 1H NMR (500 MHz, CDCl3) δ: 9.01 (s, 1 H), 8.24 (s, 2H), 7.19 (m, 2H), 
7.01 (d, J = 7.5 Hz, 2H), 4.97 (q, J = 7.0 Hz, 1H), 3.96-3.71 (m, 4H), 3.15-2.93 (m, 4H), 2.36 (s, 
3H), 1.62 (d, J = 7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 163.32, 159.20, 150.53, 147.01, 
135.72, 132.72, 131.24, 130.10 (q, J = 33.75 Hz), 126.75, 123.94, 123.61, 121.43, 119.27, 58.80, 
51.94, 51.53, 47.33, 43.23, 17.81, 13.37; HPLC purity, 98.3%; ESIMS calcd for C19H22F3N3O3S: 
441.13, Found mass [M+H]+: 442.01; HRMS (m/z): [M+H]+ calcd for C19H22F3N3O3S, 442.1334; 
found, 442.1406, exact mass(monoisotopic) from  spectrum 441.1334. 
1-(4-(2,5-dimethylphenyl)piperazin-1-yl)-2-((5-(trifluoromethyl)pyridin-2-yl)sulfonyl) 
propan-1-one (44). Starting with 7d (50 mg, 0.17 mmol) and 1-(2,5-dimethylphenyl)piperazine 
(35 µL, 0.17 mmol), white solid (51 mg, 64%) 1H NMR (500 MHz, CDCl3) δ: 9.01 (s, 1 H), 8.23 
(s, 2H), 7.19 (d, J = 7.5 Hz, 1H), 7.06-7.03 (m, 2H), 4.97 (q, J = 7.0 Hz, 1H), 3.96-3.68 (m, 4H), 
3.13-2.90 (m, 4H), 2.30 (s, 6H), 1.62 (d, J = 7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 163.28, 
159.20, 150.38, 147.02, 136.36, 135.67, 131.04, 130.25, 129.98, 129.41, 124.59, 123.94, 120.04, 
58.83, 51.93, 51.56, 47.36, 43.26, 21.13, 17.38, 13.36; HPLC purity, 99.7%; ESIMS calcd for 
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C21H24F3N3O3S: 455.15, Found mass [M+H]
+: 456.17; HRMS (m/z): [M+H]+ calcd for 
C21H24F3N3O3S, 456.1490; found, 456.1560, exact mass(monoisotopic) from  spectrum 455.1487. 
1-(4-(3,4-dichlorophenyl)piperazin-1-yl)-2-((5-(trifluoromethyl)pyridin-2-yl)sulfonyl) 
propan-1-one (45). Starting with 7d (50 mg, 0.17 mmol) and 1-(3,4-dichlorophenyl)piperazine 
(40 mg, 0.17 mmol), shiny white crystals (31 mg, 58%) 1H NMR (500 MHz, CDCl3) δ: 9.00 (s, 1 
H), 8.42-8.20 (m, 2H), 7.30 (d, J = 9.0 Hz, 1H), 6.97 (s, 1H), 6.75 (dd, J = 6.0 Hz, 1H), 4.97 (q, J 
= 7.0 Hz, 1H), 4.03-3.11 (m, 8H), 1.58 (d, J = 8.0 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 162.96, 
158.88, 150.05, 147.12, 135.78, 133.00, 130.66, 123.86, 123.54, 123.31, 121.36, 117.94, 115.92, 
58.44, 49.06, 48.78, 46.33, 42.37, 13.38; HPLC purity (methanol/water, 1:1), 95.4%; ESIMS 
[M+H]+ calcd for C19H18Cl2F3N3O3S: 497.04, Found mass [M+H]
+: 497.15; HRMS (m/z): [M+H] 




Cell culture, Chlamydia trachomatis propagation, and IFU assay: 
The human epithelial cell line HEp-2 was routinely propagated in Dulbecco's modified Eagle 
medium (DMEM; Gibco) supplemented with 2% L-glutamine and 10% fetal bovine serum (FBS) 
at 37 °C with % CO2. All infected and uninfected cell cultures were incubated at these conditions. 
Compounds stocks of the synthesized compounds were prepared in sterile dimethyl sulfoxide (50 
mg/mL) and frozen at -20 °C in 5 μL aliquots.41 
To quantify the effect of the most active compounds on C. trachomatis, HEp-2 cells were first 
seeded in a 24-well plate. Cells were infected with C. trachomatis L2 at a multiplicity of infection 
of 1, and the tested compounds were added in triplicate 8 hours post infection (hpi). At 24 hpi, cell 
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lysates, which contain C. trachomatis elementary bodies, were collected from infected HEp-2 cell 
cultures in sucrose storage medium. The resulting mixture was frozen at -80 °C and used to infect 
a fresh HEp2 cell monolayer in a series of 10-fold dilutions. After a further 24hpi, the recoverable 
EBs from the initial infection were stained using primary goat anti-MOMP antibody and a 
secondary donkey anti-goat antibody labelled with Alexa488. The fluorescent inclusions were 
counted from 15 fields of view (FOV) at 20x magnification.  IFUs were calculated as the average 
count of inclusions in each FOV corrected for the dilution factor.41, 87 In mechanism of action 
assays, we followed the same protocol described in the IFU assay. For (24h reactivation) samples, 
the DMEM medium was removed after 24hpi, and the wells were washed three times with Hanks’ 
balanced salt solution, and fresh medium without compounds was added (0.5 mL/well). 
 
Casein degradation assay: 
All recombinant, C-terminal 6X His-tagged ClpP proteins were expressed using E. coli and 
purified as previously described using a clpAPX-null E. coli strain kindly provided by Dr. Peter 
Sass.41, 42 The clpP human (NM_006012.4) and mouse (NM_017393.2) mRNA sequences were 
used to obtain the ClpP-encoding ORF minus the mitochondrial localization signal. Genes were 
then codon optimized for E. coli expression and synthesized by Integrated DNA Technologies. 
The mouse and human clpP paralogs were cloned into the pLATE31 vector (Thermo Scientific) 
as previously performed for the bacterial ClpP’s. Example purified protein samples are shown in 
Figure S2. FITC-casein (Sigma-Aldrich, C0528) was treated with Zeba 7K cutoff spin columns 
(Thermo Scientific) to remove free FITC. Assays were carried out in buffer PZ (25 mM HEPES 
[pH 7.6], 200 mM KCl, 5 mM MgCl2, 1 mM DTT, and 10% v/v of glycerol) using 100 μL 
reactions and 20 μM FITC-casein. 1 μM or 0.1 µM (for 40) of ClpP from E. coli, 1 µM mouse  
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or human ClpP, or 6 μM of ClpP1 and ClpP2 were preincubated with either 25 μg/μl compounds 
or DMSO solvent at 32°C for 30 minutes before adding FITC-casein. Reactions were monitored 
for 3 hours with readings every 3 minutes on a Tecan m Plex plate reader using an excitation 
wavelength of λex = 490 nm and an emission wavelength λem = 525 nm. Reactions were run at 
least three times using at least two independent protein purification preparations 
Antibacterial assay against additional strains:  
S. aureus USA 300 JE2, and E. coli K12 were provided by Dr. Bayles’ research lab at the 
Department of Pathology and Microbiology of the University of Nebraska Medical Center—
UNMC.  The MICs of the synthesized compounds were tested in triplicate samples, using the broth 
microdilution method as previously reported.88. The bacterial cultures were made in Muller Hinton 
Broth (MHB) using the direct colony suspension method at 1.5 X 108 CFU/mL followed by 
dilution to ~ 105 CFU/mL. The stock solutions of the tested compounds were prepared in sterile 
DMSO at 1 mg/mL concentration. Then, a serial dilution of the tested compounds were made in 
MHB, in Cellstar 96-well microtiter plates using vancomycin as a positive control and blank media 
as a negative control. 10 μL of bacterial culture was added per well followed by plates incubation 
for 16 h at optimum temperature. The MIC was categorized as the concentration at which no visible 
growth of bacteria was observed at 600 nm in a particular well using an AccuSkan, MultiSkan FC. 
The average of triplicate MIC determinations is reported (for further details please see the SI). 
Cytotoxicity assay (CCK-8):  
The immortal keratinocyte cell line (HaCaT) and HeLa 229 were cultured in DMEM media 
containing 10% FBS and 1% Penicillin/Streptomycin solution at 37 °C with 5% CO2. The cells 
were seeded separately at a density of 5000 cell per well in 96-well plates. On the next day, cells 
were treated with 50 μg/mL of the tested drugs in triplicates and as controls we used DMSO at a 
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concentration equivalent to the one used in drug-treated cells. Then, the plates were incubated for 
additional 24 h before the addition of  10 μL of the assay reagent Cell Counting Kit-8 (CCK-8) 
(DOJINDO laboratories) followed by incubation of the plates for 2 h. Corrected absorbance 
readings were determined with a 450 nm filter using a multiskan TM FC microplate photometer 
(Thermo Fischer Scientific, US).  
Mutagenic Studies – SMART: 
We assessed the mutagenicity of the compounds by Somatic Mutation and Recombination Test – 
SMART using wing-somatic cells of Drosophila melanogaster. 89, 90  The following 3 crosses of 
mutant flies were set up: 1) Standard cross (ST): flare-3 (flr3) virgin females, with genetic 
constituent flr3/In(3LR)TM3, ri pp sep I(3)89Aa bx34e e BdS crossed with multiple wing hairs (mwh) 
males, with genetic constituent y; mwh jv and, 2) High bioactivation (HB) cross: ORR; flare (ORR; 
flr3) virgin female, with genetic constituent ORR; flr3 / In (3LR) TM3, ri pp sep I(3)89 Aa bx 34e 
BdS crossed with mwh males. The ORR;flr3 strain carries the chromosomes 1 and 2 from a DDT-
resistant Oregon R (R) line, which contain genes responsible for the high level of metabolizing 
enzymes of the cytochrome P450, P(CYP)6 A2 type.89 
Eggs were collected from flies of the two different crosses in culture flasks containing a solid agar-
agar base (5% w/v), covered by a layer of live baker`s yeast supplemented with sugar for 8 hours. 
Third instar larvae (72 ± 4 h) were washed out of the culture bottles with tap water and collected 
with a fine meshed strainer. Larvae groups were transferred to glass vials containing hydrated 
alternative medium (instant mashed potato flakes Yoki®) and exposed to compounds 11, 20, 24, 
26, 40 and 41 at 0.25, 0.5, and 1.0 mM final concentrations. Solvent (Milli-Q water, 1% of Tween-
80 and 3% ethanol) was used as a negative control. 
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The hatched flies of the marker heterozygote (mwh +/+ flr3) and the balancer heterozygote (mwh 
+/+ TM3, Bds) genotypes were collected and fixed in 70% ethanol. Wings were removed, mounted 
on slides containing Faure’s solution (30 g of gum Arabic, 50 g of chloral hydrate, 20 mL of 
glycerol, and 50 mL of water) and analyzed under optical microscope (400×) for the occurrence 
of different types of mutant spots.91 
The statistical analysis was performed as described by Frei and Würgler,90 using the chi-squared 
test. Results were considered statistically significant when p < 0.05. The frequencies of each spot 
(single small, single large, or twin) and the total frequency of spots per fly, for each treatment, 
were compared in pairs (i.e. negative control versus compound-treated). 
Metabolic Stability: 
The in vitro metabolism stability experiment was done using human liver microsomes (XenoTech, 
LLC, Lenexa, KS, USA) for phase I metabolism. The results were expressed as the percentage of 
drug remaining (solution were 1 µM in 0.1% methanol) and the studies were performed in triplicate 
as described previously.92  For the microsomal stability test we used a solution of phosphate buffer 
(100 mM, pH 7.4), microsomal protein (1.0 mg/mL), magnesium chloride (10 mM) and NADPH 
(2 mM) at a final volume of 1.0 mL.  This mixture was pre-incubated at 37 °C for 10 min in a 
water bath maintained at 60 rpm. The reaction was initialized by adding the selected compounds 
(1 µg/mL). Aliquots (100 µL) were collected at 0, 5, 15, 20, 30, 45 and 60 min.  The reaction was 
quenched by adding MeOH (300 µL) containing IS (100 ng/mL). The aliquot and quenching 
reaction were contained in a 1.5 mL Eppendorf tube. The incubation without the addition of 
NADPH was used as negative control. Testosterone was incubated similarly as positive control 
substrates. Then, 5 μL samples of the supernatants were analyzed by LC-MS/MS.  
Page 44 of 71
ACS Paragon Plus Environment






























































A: Shimadzu LC-MS/MS system (LC-MS/MS 8060, Shimadzu, Japan) was utilized for analysis.  
The LC system consisted of two LC‐30 AD pumps and a CTO‐30AS column oven plus an auto‐
sampler (SIL‐30AC), which was used to inject 10 μL aliquots of the processed samples. The 
MS/MS system operated at unit resolution in the multiple reaction monitoring (MRM) mode.  The 
following precursor ion > product ion combinations were used: 489.95>280.15, 510.05>280.05, 
417.10>280.10, 416.15>98.10 AND 414.10>176.25 m/z for 40, 37, 25, 24, and 11, respectively. 
The compound dependent mass spectrometer parameters, such as temperature, voltage, gas 
pressure, etc., were optimized by auto method optimization via precursor ion search for each 
analyte and the internal standard (IS) using a 0.5 µg/mL solution in methanol. 
B: Chromatographic separation was achieved on an ACE Excel C18 column (1.7µm, 100 X 2.1 
mm, from Advance Chromatography Technologies LTD., UK) with a Phenomenex C18 column 
guard (Phenomenex, Torrance, CA). The mobile phase consisted of formic acid in water (0.1%, 
solvent A) and methanol (MeOH) (solvent B) using a total flow rate of 0.25 mL/min. The 
chromatographic separation was achieved using 5.0 min gradient elution. The initial mobile phase 
composition was 35% B, increasing to 90% B over 4 min, and finally brought back to initial 
condition of 35% B in 0.10 min followed by 1-min re-equilibration. The injection volume (5 μL) 
was consistent for all samples. 
Mouse plasma stability: 
The tested compounds were dissolved in DMSO to yield 2.5 mM solutions. Mouse plasma was 
diluted to 80% with PBS and heated at 37 ºC before the assay. The tested compounds were 
incubated with the preheated plasma solution (final concentration: 50 M) in a shaking water bath 
at 37 ºC at six different time points: 0, 15, 30, 60, 90, and 120 min. Experiments were 
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independently conducted in triplicate. At the end of the incubation time, 50 L of sample were 
collected and mixed with 200 L of cold acetonitrile to stop the reaction. Solutions were vortex-
mixed and then centrifuged at 4 ºC and 14000 rpm for 15 min. Supernatants were diluted in 
methanol:water (50:50 v/v) and analyzed by HPLC-PDA-ESI-SQ-MS. Peak areas of test 
compounds were computed for each incubation time and relative levels to time zero are reported. 
Enalapril was used as a positive control during incubation.  
SGA stability: 
The tested compounds were dissolved in DMSO to yield 1 mM. Compounds were incubated with 
SGF solution (final concentration: 50 M) in a shaking water bath at 37 ºC for four different time 
points: 0, 30, 60, and 120 min. Experiments were independently conducted in triplicate. At the end 
of the incubation, 125 L of sample solution was taken and 375 L of acetonitrile was added to 
stop the reaction. The solutions were vortex-mixed and centrifuged at 25 ºC and 15000 rpm for 15 
min. The supernatant was diluted in methanol:water (50:50 v/v) and analyzed by HPLC-MS. The 
percentage of compound remaining at the individual time points relative to the 0 minute sample is 
reported based on the peak area of the test compound.  
The HPLC-PDA-ESI-SQ-MS analysis was performed using a Waters Alliance e2695 system with 
a Phenomenex Kinetex XB-C18 (4.6 x 150 mm, 5 m particle size) column, coupled to a Waters 
2998 photodetector array and a Waters SQD2 single quadrupole mass spectrometer with an ESI 
source. Gradient elution was utilized in the chromatographic separation method using 0.1% formic 
acid in water (mobile phase A), and methanol (mobile phase B), with the following program: 0-9 
min 75 % B; 9-10 min 75-95 % B; 10 min 95% B. The flow rate was constant at 0.4 mL min-1. 
After each sample injection, the gradient was returned to its initial condition in 16 min. The 
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injection volume was 5 L, and the column temperature was 40 ºC. The mass spectrometer was 
operated in positive ion mode with a probe capillary voltage of 3.0 kV. The sampling cone voltage 
was set to 45.0 V. The source and desolvation gas temperatures were set at 150°C and 350°C, 
respectively. The nitrogen gas desolvation flow rate was 600 L h–1 and the cone gas flow rate was 
10 L h–1. The mass spectrometer was calibrated across the range of m/z 20–2023 with a sodium 
and cesium iodide solution. Data were acquired in scan mode with scan duration of 0.2 sec; in SIR 
mode for each test compound based on the m/z value for [M+H]+ adduct ions, and with unit 
resolution. Data acquisition and processing were conducted using MassLynx, version 4.1 (Waters 
Corp.).  
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EB, elementary body; RB, reticulate body; STI, sextually transmitted infection; STDs, sexually 
transmitted diseases; ACP, Activators of Cylindrical protease; PyBOP, Benzotriazole-1-yl-oxy-
tris-pyrrolidino-phosphonium hexafluorophosphate; HBTU, N,N,N′,N′-Tetramethyl-O-(1H-
benzotriazol-1-yl)uronium hexafluorophosphate; HATU, 1-[Bis(dimethylamino)methylene]-1H-
1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate; DIPEA, N, N 
Diisopropylethylamine; IFA, Immunofluorescence assay; IFU, Inclusion Forming Unit;  Hep-2, 
Human epithelial type 2; HBD, hydrogen bond donor; HBA, hydrogen bond acceptor; SDS, 
sodium dodecyl sulfate; Suc-Luc-Tyr-AMC, Succinic acid-Leucin-Tyrosin- 7-amino-4-methyl-
2H-chromen-2-one; TLC, thin layer chromatography; b rs, broad signal; DMEM, Dulbecco's 
Modified Eagle Medium.   
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This is the original figure, we are including a second cover art. The quality of both figures is different in PC 
vs Mac, thus, we are not sure which one will be better for you. 
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Figure 1. Structures of ADEP and ACP compounds. 
144x75mm (300 x 300 DPI) 
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Figure 2. Quantification of Chlamydial growth in the presence of selected ACP derivatives (numbered) and 
antibiotics spectinomycin (Spec) and penicillin (Pen) as compared to an untreated (UTD) control at 24 h 
post-infection. Results are reported as an average with standard deviation on a log10 scale and represent a 
minimum of two biological replicates. 
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Figure 3. (a) Immunofluorescence images of the effects of selected compounds on chlamydial inclusion 
growth. In blue, HEp-2 cells nuclei; in green, chlamydial inclusions. Images were acquired at 24h post-
infection. (b) Cell morphology images using an EVOS FL auto cell imaging microscope. 
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Figure 4. (a) Dose-response curve for the effect of 40 reported on a log10 scale. (b) Immunofluorescence 
analysis of 40 inhibitory effect. In green, chlamydial inclusions; in blue, HEp-2 cell nuclei. 
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Figure 5. (a) Quantification of Chlamydial growth in the presence of selected ACP derivatives (40 and 
ACP1b) and antibiotics Azithromycin (Azith) and Doxycycline (Dox) as compared to an untreated (UTD) 
control at 24h post-infection. (b) Immunofluorescence analysis of the tested compounds inhibitory effect; in 
green, chlamydial inclusions; in blue, HEp-2 cells nuclei. 
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Figure 6. (a) Investigation of the bacteriostatic or bactericidal activity of 40 as measured by IFU output and 
reported on a log10 scale. (b) Immunofluorescence analysis of 40 impact 24h after its removal 
(Reactivation) in comparison with untreated (UTD) samples at 24h post-infection. In green, chlamydial 
inclusions; in blue, HEp-2 cell nuclei. 
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Figure 7. In vitro protease assay shows the degradation of casein (unlabeled) by three different recombinant 
ClpP preparations with or without the compounds as assessed by SDS-PAGE analysis. Ec = Escherichia coli 
 Ctr = Chlamydia trachomatis  Hs = Homo sapiens  Mm = Mus musculus. DMSO is a negative control. Note 
the mammalian ClpP orthologs migrate slightly lower than casein in the gels. The top band in all images is 
casein and the lower band is the respective ClpP. Molecular weight markers (in kDa) are present in lane 1 of 
each gel. 
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Figure 8. Toxicity analysis of the most active compounds against HeLa 229 and human keratinocytes 
(HaCaT) at 50 µg/mL. 
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Figure 9. Time-dependent metabolic stability of the tested compounds in human liver microsomes fortified 
with NADPH and without NADPH (negative control). Metabolic elimination profiles (% turnover or amount 
remaining vs. incubation time). Data shown as mean±S.D (n=3). 
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Figure 10. Stability profile in mouse plasma (a) and stimulated gastric fluid (b). Relative concentration is 
represented as a function of incubation time between the tested compound and mouse plasma and 
simulated gastric fluid (SGF, pH 1.2). Error bars represent SD of three independent experiments. 
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Figure 11. SAR graphical summary. 
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